

(19)  **Canadian  
Intellectual Property  
Office**  
  
An Agency of  
Industry Canada

**Office de la Propriété,  
Intellectuelle  
du Canada**  
  
Un organisme  
d'Industrie Canada

(11) **CA 2 394 722** (13) **A1**

(40) 28.06.2001  
(43) 28.06.2001

(12)

(21) **2 394 722**

(22) **08.12.2000**

(51) Int. Cl. 7: **C11D 3/386, D06M 16/00,  
C11D 3/39**

(85) **18.06.2002**

(86) **PCT/EP00/12529**

(87) **WO01/046356**

(30) **99310431.4 EP 22.12.1999**

(71) **UNILEVER PLC,  
Unilever House  
Blackfriars  
EC4P 4BQ, LONDON, XX (GB).**

(72) **PARRY, NEIL JAMES (GB).  
VAN DER LOGT, CORNELIS PAUL ERIK (NL).  
LITTLE, JULIE (GB).  
HOWELL, STEVEN (GB).**

(74) **BERESKIN & PARR**

(54) **PROCEDE DE TRAITEMENT DE TISSUS**  
(54) **METHOD OF TREATING FABRICS**

(57)

There is provided a method of delivering a benefit agent to fabric for exerting a pre-determined activity, wherein the fabric is pre-treated with a multi-specific binding molecule which has a high binding affinity to said fabric through one specificity and is capable of binding to said benefit agent through another specificity, followed by contacting said pre-treated fabric with said benefit agent, to enhance said pre-determined activity to said fabric. Preferably, the binding molecule is an antibody or fragment thereof, or a fusion protein comprising a cellulose binding domain and a domain having a high binding affinity to another ligand which is directed to said benefit agent. The method is useful for example for stain removal, perfume delivery, and treating collars and cuffs for wear.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number  
**WO 01/46356 A3**(51) International Patent Classification<sup>7</sup>: **CIID 3/386.**  
3/39, D06M 16/00

(21) International Application Number: PCT/EP00/12529

(22) International Filing Date: 8 December 2000 (08.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
99310431.4 22 December 1999 (22.12.1999) EP(71) Applicant (for all designated States except AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, IN, KE, LK, LS, MN, MW, MZ, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW): **UNILEVER N.V.** [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).(71) Applicant (for AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, KE, LK, LS, MN, MW, MZ, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW only): **UNILEVER PLC** [NL/NL]; Unilever House, Blackfriars, London, Greater London EC4P 4BQ (NL).(71) Applicant (for IN only): **HINDUSTAN LEVER LTD** [IN/IN]; Hindustan Lever House, 165-166 Backbay Reclamation, Mumbai\_400 020 (IN).(72) Inventors: **HOWELL, Steven**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). **LITTLE, Julie**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK 1LQ (GB). **VAN DER LOGT,****Cornelis, Paul, Erik**; Unilever Research Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen Vlaardingen (NL). **PARRY, Neil, James**; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB).(74) Agent: **KAN, Jacob, Hendrik**; Unilever Research Vlaardingen, Patent Department, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen Vlaardingen (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report

(88) Date of publication of the international search report:  
10 January 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF TREATING FABRICS

(57) Abstract: There is provided a method of delivering a benefit agent to fabric for exerting a pre-determined activity, wherein the fabric is pre-treated with a multi-specific binding molecule which has a high binding affinity to said fabric through one specificity and is capable of binding to said benefit agent through another specificity, followed by contacting said pre-treated fabric with said benefit agent, to enhance said pre-determined activity to said fabric. Preferably, the binding molecule is an antibody or fragment thereof, or a fusion protein comprising a cellulose binding domain and a domain having a high binding affinity to another ligand which is directed to said benefit agent. The method is useful for example for stain removal, perfume delivery, and treating collars and cuffs for wear.

WO 01/46356 A3

METHOD OF TREATING FABRICSTECHNICAL FIELD

5           The present invention generally relates to the use of multi-specific molecules and in particular multi-specific antibodies for treating fabrics, especially garment, with a benefit agent. More in particular, the invention relates to a method of delivering a benefit agent to fabric for exerting a  
10 pre-determined activity. In a preferred embodiment, the invention relates to a method of stain bleaching on fabrics which comprises using multi-specific molecules to pre-treat the stained fabric.

15

BACKGROUND AND PRIOR ART

Multi-functional, in particular multi-specific agents including bi-specific agents are well known in the art. Gluteraldehyde, for example, is widely used as a coupling or  
20 crosslinking agent. The development of bi- and multi-functional antibodies has opened a wide scale of new opportunities in various technological fields, in particular in diagnostics but also in the detergent area.

WO-A-98/56885 (Unilever) discloses a bleaching enzyme  
25 which is capable of generating a bleaching chemical and having a high binding affinity for stains present on fabrics, as well as an enzymatic bleaching composition comprising said bleaching enzyme, and a process for bleaching stains on fabrics. The binding affinity may be formed by a part of the  
30 polypeptide chain of the bleaching enzyme, or the enzyme may comprise an enzyme part which is capable of generating a bleach chemical that is coupled to a reagent having the high binding affinity for stains present on fabrics. In the latter case the reagent may be bispecific, comprising one  
35 specificity for stain and one for enzyme. Examples of such bispecific reagents mentioned in the disclosure are

antibodies, especially those derived from *Camelidae* having only a variable region of the heavy chain polypeptide ( $V_{HH}$ ), peptides, peptidomimics, and other organic molecules. The enzyme which is covalently bound to one functional site of the antibody usually is an oxidase, such as glucose oxidase, galactose oxidase and alcohol oxidase, which is capable of forming hydrogen peroxide or another bleaching agent. Thus, if the multi-specific reagent is an antibody, the enzyme forms an enzyme/antibody conjugate which constitutes one ingredient of a detergent composition. During washing, said enzyme/antibody conjugate of the detergent composition is targeted to stains on the clothes by another functional site of the antibody, while the conjugated enzyme catalyzes the formation of a bleaching agent in the proximity of the stain and the stain will be subjected to bleaching.

WO-A-98/00500 (Unilever) discloses detergent compositions wherein a benefit agent is delivered onto fabric by means of peptide or protein deposition aid having a high affinity for fabric. The benefit agent can be a fabric softening agent, perfume, polymeric lubricant, photosensitive agent, latex, resin, dye fixative agent, encapsulated material, antioxidant, insecticide, anti-microbial agent, soil repelling agent, or a soil release agent. The benefit agent is attached or adsorbed to a peptide or protein deposition aid having a high affinity to fabric. Preferably, the deposition aid is a fusion protein containing the cellulose binding domain of a cellulase enzyme. The compositions are said to effectively deposit the benefit agent onto the fabric during the wash cycle.

According to DE-A-196 21 224 (Henkel), the transfer of textile dyes from one garment to another during a washing or rinsing process may be inhibited by adding antibodies against the textile dye to the wash or rinse liquid.

WO-A-98/07820 (P&G) discloses amongst others rinse treatment compositions containing antibodies directed at cellulase and standard softener actives (such as DEQA).

It has now surprisingly been found that a two-step process in which multispecific molecules are bound to pre-treat a fabric, followed by a step in which a benefit agent is bound to said multispecific molecules will result in a more efficient targeting of the benefit agent to the fabric and, accordingly, to a process in which the benefit agent can exert its aimed activity more efficiently.

Based on this principle, the invention can be practiced in various embodiments, which will be explained below.

#### SUMMARY OF THE INVENTION

According to one aspect of the present invention, there is provided a method of delivering a benefit agent to fabric for exerting a pre-determined activity, which comprises pre-treating said fabric with a multi-specific binding molecule, said binding molecule having a high binding affinity to said fabric through one specificity and is capable of scavenging and binding to said benefit agent through another specificity, followed by contacting said pre-treated fabric with said benefit agent to exert said pre-determined activity to said fabric.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide and amino acid sequence of the HindIII/EcoRI insert of plasmid Fv4715-myc encoding pelB leader-VH4715 and pel leader-VL4715.

Figure 2 shows the nucleotide and amino acid sequence of the HindIII/EcoRI insert of plasmid scFv4715-myc encoding pelB leader-VH4715-linker-VL4715.

Figure 3 shows the nucleotide and amino acid sequence of the HindIII/EcoRI insert of plasmid Fv3299-hydro2 encoding pelB leader-VH3299 and pel leader-VL3299 with hydrophil2 tail.

Figure 4 shows the nucleotide and amino acid sequence of the HindIII/EcoRI insert of plasmid Fv3418 encoding pelB leader-VH3418 and pel leader-VL3418.

Figure 5 shows the nucleotide and amino acid sequence of the HindIII/EcoRI insert of plasmid pOR4124 encoding pelB leader-VLlys-linker-VHlys.

Figure 6 shows that an activated surface can capture glucose oxidase (A, hCG then Bi-head then glucose oxidase; B, hCG then glucose oxidase; C, no hCG then Bi-head then glucose oxidase)

Figure 7 gives a diagrammatic view of a cloning strategy to obtain a bi-head antibody.

Figure 8 shows the alignment of bi-head predicted amino acid sequences. The kabat CDRs, purification and detection tails are boxed, amino acid differences are in bold type.

Figure 9 shows that a red wine surface activated with bi-head antibody (Fig 9 A) can scavenge more glucose oxidase than can be bound to a wine surface when bi-head and glucose oxidase are mixed together in a single step (Fig 9 B).

Figure 10 shows the DNA construct pUR4536

Figure 11 shows the DNA construct pPIC9

Figure 12 shows the DNA sequence of anti-RR6-VHH8-his-CBD.

#### DETAILED DESCRIPTION OF THE INVENTION

The invention provides in one aspect the delivery of a multi-specific binding molecule to fabric to which it has a high binding affinity through one specificity, in order to enable a benefit agent which is capable of scavenging and binding to said binding molecule through another specificity to exert a pre-determined activity in close proximity of the pre-treated fabric.

As used herein, the term "multi-specific binding molecule" means a molecule which at least can associate onto fabric and also capture benefit agent. Similarly, the term

"bi-specific binding molecule" as used herein indicates a molecule which can associate onto fabric and capture benefit agent.

In a first, pre-treating step the binding molecule is directly delivered to the fabric, for example a garment, preferably at relatively high concentration, thus enabling the binding molecule to bind to the fabric in an efficient way. In a second step, the binding molecule is contacted with the benefit agent, which is usually contained in a dispersion or solution, preferably an aqueous solution, thus enabling the benefit agent to bind to the binding molecule through another specificity of said binding molecule.

The multi-specific binding molecule can be any suitable molecule with at least two functionalities, i.e. having a high binding affinity to the fabric to be treated and being able to bind to a benefit agent, thereby not interfering with the pre-determined activity of the benefit agent and possible other activities aimed. In a preferred embodiment, said binding molecule is an antibody, or an antibody fragment, or a derivative thereof.

The present invention can be advantageously used in, for example, treating stains on fabrics, preferably by bleaching said stains. In a first step, the binding molecule is applied, preferably on the stain. The benefit agent which is then bound to the binding molecule preferably is an enzyme or enzyme part, more preferably an enzyme or enzyme capable of catalysing the formation of a bleaching agent under conditions of use. The enzyme or enzyme part is usually contacted to the binding molecule (and the stains) by soaking the pre-treated fabric into a dispersion or solution comprising the enzyme or enzyme part. The dispersion or solution which usually but not necessarily is an aqueous dispersion or solution also comprises ingredients generating the bleaching agent, or such ingredients are added later. Preferably, the enzyme or enzyme part and said other ingredients generating a bleach are contained in a washing

composition, and the step of binding the enzyme (or part thereof) to the binding molecule and generating the bleaching agent is performed during the wash. Alternatively, the benefit agent may be added prior to or after washing, for  
5 example in the rinse or prior to ironing.

The targeting of the benefit agent according to the invention which in this typical example is a bleaching enzyme, results in a higher concentration of bleaching agent in the proximity of the stains to be treated, before, during  
10 or after the wash. Alternatively, less bleaching enzyme is needed as compared to known non-targeting or less efficient targeting methods of treating stains.

Another typical and preferred example of the use of the present invention is to direct a fragrance (such as a  
15 perfume) to fabric to deliver or capture the fragrance so that it is released over time. A further typical use of the present invention is treating a fabric where the colour is faded by directing a benefit agent to the area in order to colour that region. Similarly, a damaged area of a fabric can  
20 be (pre-)treated to direct a repair of cellulose fibers which are bound by the antibodies to this area. These agents are for example suitably added to the pre-treated fabric after washing, in the rinse.

Other applications, such as using fabric softening  
25 agents, polymeric lubricants, photoprotective agents, latexes, resins, dye fixative agents, encapsulated materials, antioxidants, insecticides, anti-microbial agents, soil repelling agents or soil release agents, as well as other agents of choice, and ways and time of adding the agents to  
30 the pre-treated fabric are fully within the ordinary skill of a person skilled in the art.


In order to be more fully understood, certain elements of the present invention will be described hereinafter in more detail. Reference is also made to WO-A-  
35 98/56885, referred to above, the content of which is incorporated herewith by reference.



### 1.0 Binding molecules

In the first step according to the invention a multi-specific binding molecule is delivered to fabric, said binding molecule having a high affinity to said area through one specificity.

The degree of binding of a compound A to another molecule B can be generally expressed by the chemical equilibrium constant  $K_d$  resulting from the following reaction:



The chemical equilibrium constant  $K_d$  is then given by:

$$K_d = \frac{[A][B]}{[A \equiv B]}$$

Whether the binding of a molecule to the fabric is specific or not can be judged from the difference between the binding ( $K_d$  value) of the molecule to one type of fabric, versus the binding to another type of fabric material. For applications in laundry, said material will be a fabric such as cotton, polyester, cotton/polyester, or wool. However, it will usually be more convenient to measure  $K_d$  values and differences in  $K_d$  values on other materials such as a polystyrene microtitre plate or a specialised surface in an analytical biosensor. The difference between the two binding constants should be minimally 10, preferably more than 100, and more preferably, more than 1000. Typically, the molecule should bind to the fabric, or the stained material, with a  $K_d$  lower than  $10^{-4}$  M, preferably lower than  $10^{-6}$  M and could be  $10^{-10}$  M or even less. Higher binding affinities ( $K_d$  of less than  $10^{-5}$  M) and/or a larger difference between the one type of fabric and another type (or background binding) would increase the deposition of the benefit agent. Also, the

weight efficiency of the molecule in the total composition would be increased and smaller amounts of the molecule would be required.

Several classes of binding molecules can be envisaged which deliver the capability of specific binding to fabrics, to which one would like to deliver the benefit agent. In the following we will give a number of examples of such molecules having such capabilities, without pretending to be exhaustive. Reference is also made in this connection to WO 98/56885 (Unilever), the disclosure of which is incorporated herein by reference.

### 1.1 Antibodies

Antibodies are well known examples of compounds which are capable of binding specifically to compounds against which they were raised. Antibodies can be derived from several sources. From mice, monoclonal antibodies can be obtained which possess very high binding affinities. From such antibodies, Fab, Fv or scFv fragments, can be prepared which have retained their binding properties. Such antibodies or fragments can be produced through recombinant DNA technology by microbial fermentation. Well known production hosts for antibodies and their fragments are yeast, moulds or bacteria.

A class of antibodies of particular interest is formed by the Heavy Chain antibodies as found in Camelidae, like the camel or the llama. The binding domains of these antibodies consist of a single polypeptide fragment, namely the variable region of the heavy chain polypeptide ( $V_{HH}$ ). In contrast, in the classic antibodies (murine, human, etc.), the binding domain consists of two polypeptide chains (the variable regions of the heavy chain ( $V_H$ ) and the light chain ( $V_L$ )). Procedures to obtain heavy chain immunoglobulins from Camelidae, or (functionalized) fragments thereof, have been described in WO-A-94/04678 (Casterman and Hamers) and WO-A-94/25591 (Unilever and Free University of Brussels).

Alternatively, binding domains can be obtained from the  $V_H$  fragments of classical antibodies by a procedure termed "camelization". Hereby the classical  $V_H$  fragment is transformed, by substitution of a number of amino acids, into a  $V_{HH}$ -like fragment, whereby its binding properties are retained. This procedure has been described by Riechmann et al. in a number of publications (J. Mol. Biol. (1996) 259, 957-969; Protein. Eng. (1996) 9, 531-537, Bio/Technology (1995) 13, 475-479). Also  $V_{HH}$  fragments can be produced through recombinant DNA technology in a number of microbial hosts (bacterial, yeast, mould), as described in WO-A-94/29457 (Unilever).

Methods for producing fusion proteins that comprise an enzyme and an antibody or that comprise an enzyme and an antibody fragment are already known in the art. One approach is described by Neuberger and Rabbits (EP-A-194 276). A method for producing a fusion protein comprising an enzyme and an antibody fragment that was derived from an antibody originating in *Camelidae* is described in WO-A-94/25591. A method for producing bispecific antibody fragments is described by Holliger et al. (1993) PNAS 90, 6444-6448.

WO-A-99/23221 (Unilever) discloses multivalent and multispecific antigen binding proteins as well as methods for their production, comprising a polypeptide having in series two or more single domain binding units which are preferably variable domains of a heavy chain derived from an immunoglobulin naturally devoid of light chains, in particular those derived from a Camelid immunoglobulin.

An alternative approach to using fusion proteins is to use chemical cross-linking of residues in one protein for covalent attachment to the second protein using conventional coupling chemistries, for example as described in: Bioconjugate Techniques, G.T. Hermanson, ed. Academic Press, Inc. San Diego, CA, USA. Amino acid residues incorporating sulphhydryl groups, such as cysteine, may be covalently attached using a bispecific reagent such as succinimidyl-

maleimidophenylbutyrate (SMPB), for example. Alternatively, lysine groups located at the protein surface may be coupled to activated carboxyl groups on the second protein by conventional carbodiimide coupling using 1-ethyl-3-(3-  
5 dimethylaminopropyl] carbodiimide (EDC) and N-hydroxy-succinimide (NHS).

A particularly attractive feature of antibody binding behaviour is their reported ability to bind to a "family" of structurally-related molecules. For example, in Gani et al.  
10 (J. Steroid Biochem. Molec. Biol. 48, 277-282) an antibody is described that was raised against progesterone but also binds to the structurally-related steroids, pregnanediolone, pregnanolone and 6-hydroxy-progesterone. Therefore, using the same approach, antibodies could be isolated that bind to a  
15 whole "family" of stain chromophores (such as the polyphenols, porphyrins, or carotenoids as described below). A broad action antibody such as this could be used to treat several different stains when coupled to a bleaching enzyme.

## 20 1.2 Fusion proteins comprising a cellulose binding domain (CBD)

Another class of suitable and preferred binding molecules for the purpose of the present invention are fusion proteins comprising a cellulose binding domain and a domain  
25 having a high binding affinity for another ligand. The cellulose binding domain is part of most cellulase enzymes and can be obtained therefrom. CBDs are also obtainable from xylanase and other hemicellulase degrading enzymes. Preferably, the cellulose binding domain is obtainable from a  
30 fungal enzyme origin such as *Humicola*, *Trichoderma*, *Thermonospora*, *Phanerochaete*, and *Aspergillus*, or from a bacterial origin such as *Bacillus*, *Clostridium*, *Streptomyces*, *Cellulomonas* and *Pseudomonas*. Especially preferred is the cellulose binding domain obtainable from *Trichoderma reesei*.

35 In the fusion protein, the cellulose binding domain is fused to a second domain having a high binding affinity to

another ligand. Preferably, the cellulose binding domain is connected to the domain having a high binding affinity to another ligand by means of a linker, consisting of 2-15, preferably 2-5 amino acids.

5           The second domain having a high binding affinity to another ligand may, for example, be an antibody or an antibody fragment. Especially preferred are heavy chain antibodies such as found in *Camelidae*.

10           The CBD antibody fusion binds to the fabric via the CBD region, thereby allowing the antibody domain to bind to corresponding antigens that comprise or form part of the benefit agent.

### 1.3 Peptides

15           Peptides usually have lower binding affinities to the substances of interest than antibodies. Nevertheless, the binding properties of carefully selected or designed peptides can be sufficient to provide the desired selectivity to bind a benefit agent or to be used in an aimed process, for  
20           example an oxidation process.

          A peptide which is capable of binding selectively to a substance which one would like to oxidise, can for instance be obtained from a protein which is known to bind to that specific substance. An example of such a peptide would be a  
25           binding region extracted from an antibody raised against that substance. Other examples are proline-rich peptides that are known to bind to the polyphenols in wine.

          Alternatively, peptides which bind to such substance can be obtained by the use of peptide combinatorial  
30           libraries. Such a library may contain up to  $10^{10}$  peptides, from which the peptide with the desired binding properties can be isolated. (R.A. Houghten, Trends in Genetics, Vol 9, no 6, 235-239). Several embodiments have been described for this procedure (J. Scott et al., Science (1990) 249, 386-390;  
35           Fodor et al., Science (1991) 251, 767-773; K. Lam et al., Nature (1991) 354, 82-84; R.A. Houghten et al., Nature (1991)

354, 84-86).

Suitable peptides can be produced by organic synthesis, using for example the Merrifield procedure (Merrifield (1963) J.Am.Chem.Soc. 85, 2149-2154).

- 5 Alternatively, the peptides can be produced by recombinant DNA technology in microbial hosts (yeast, moulds, bacteria) (K.N. Faber et al. (1996) Appl. Microbiol. Biotechnol. 45, 72-79).

10 1.4 Peptidomimics

- In order to improve the stability and/or binding properties of a peptide, the molecule can be modified by the incorporation of non-natural amino acids and/or non-natural chemical linkages between the amino acids. Such molecules are  
15 called peptidomimics (H.U. Saragovi et al. (1991) Bio/Technology 10, 773-778; S. Chen et al. (1992) Proc.Natl.Acad. Sci. USA 89, 5872-5876). The production of such compounds is restricted to chemical synthesis.

20 1.5 Other organic molecules

The list on proteins and peptides described so far are by no means exhaustive. Other proteins, for example those described in WO-A-00/40968, which is incorporated herein by reference, can also be used.

- 25 It can be readily envisaged that other molecular structures which need not be related to proteins, peptides or derivatives thereof, can be found which bind selectively to substances one would like to oxidise with the desired binding properties. For example, certain polymeric RNA molecules  
30 which have been shown to bind small synthetic dye molecules (A. Ellington et al. (1990) Nature 346, 818-822). Such binding compounds can be obtained by the combinatorial approach, as described for peptides (L.B. McGown et al. (1995), Analytical Chemistry, 663A-668A).

- 35 This approach can also be applied for purely organic compounds which are not polymeric. Combinatorial procedures

for synthesis and selection for the desired binding properties have been described for such compounds (Weber et al. (1995) Angew. Chem. Int. Ed. Engl. **34**, 2280-2282; G. Lowe (1995), Chemical Society Reviews **24**, 309-317; L.A. Thompson et al. (1996) Chem. Rev. **96**, 550-600). Once suitable binding compounds have been identified, they can be produced on a larger scale by means of organic synthesis.

## 2. The benefit agent

10 In general, the benefit agent can be scavenged by the binding molecule and retain at least a substantial part of its desired activity. The benefit agent is chosen to impart a benefit onto the garment. This benefit can be in the form of a bleaching agent (produced by, for example, bleaching  
15 enzymes) that can de-colourise stains, fragrances, colour enhancers, fabric regenerators, softening agents, finishing agents/protective agents, and the like. These will be described in more detail below.

### 2.1 Bleaching enzymes

Suitable bleaching enzymes which are useful for the purpose of the present invention are capable of generating a bleaching chemical.

The bleaching chemical may be hydrogen peroxide which  
25 is preferably enzymatically generated. The enzyme for generating the bleaching chemical or enzymatic hydrogen peroxide-generating system is generally selected from the various enzymatic hydrogen peroxide-generating systems which are known in the art. For example, one may use an amine  
30 oxidase and an amine, an amino acid oxidase and an amino acid, cholesterol oxidase and cholesterol, uric acid oxidase and uric acid, or a xanthine oxidase with xanthine. Alternatively, a combination of a C<sub>1</sub>-C<sub>4</sub> alkanol oxidase and a C<sub>1</sub>-C<sub>4</sub> alkanol is used, and especially preferred is the  
35 combination of methanol oxidase and ethanol. The methanol oxidase is preferably isolated from a catalase-negative

Hansenula polymorpha strain. (see for example EP-A-U 244 920 of Unilever). The preferred oxidases are glucose oxidase, galactose oxidase and alcohol oxidase.

A hydrogen peroxide-generating enzyme could be used  
5 in combination with activators which generate peracetic acid. Such activators are well-known in the art. Examples include tetraacetythylenediamine (TAED) and sodium nonanoyl-oxybenzenesulphonate (SNOBS). These and other related compounds are described in fuller detail by Grime and Clauss  
10 in Chemistry & Industry (15 October 1990) 647-653.

Alternatively, a transition metal catalyst could be used in combination with a hydrogen peroxide generating enzyme to increase the bleaching power. Examples of manganese catalysts are described by Hage et al. (1994) Nature 369, 637-639.

15 Alternatively, the bleaching chemical is hypohalite and the enzyme is then a haloperoxidase. Preferred haloperoxidases are chloroperoxidases and the corresponding bleaching chemical is hypochlorite. Especially preferred chloroperoxidases are vanadium chloroperoxidases, for example  
20 from *Curvularia inaequalis*.

Alternatively, peroxidases or laccases may be used. The bleaching molecule may be derived from an enhancer molecule that has reacted with the enzyme. Examples of laccase/enhancer systems are given in WO-A-95/01426. Examples  
25 of peroxidase/enhancer systems are given in WO-A-97/11217.

Suitable examples of bleaches include also photobleaches. Examples of photobleaches are given in EP-A-379 312 (British Petroleum), which discloses a water-insoluble photobleach derived from anionically substituted  
30 porphine, and in EP-A-035 470 (Ciba Geigy), which discloses a textile treatment composition comprising a photobleaching component.

## 2.2 Fragrances

35 The benefit agent can be a fragrance (perfume), thus through the application of the invention it is able to impart



onto the fabric a fragrance that will remain associated with the fabric for a longer period of time than conventional methods. Fragrances can be captured by the binding molecule directly, more preferable is the capture of "packages" or vesicles containing fragrances. The fragrances or perfumes may be encapsulated, e.g. in latex microcapsules. Of special interest are plant oil bodies, for instance those which can be isolated from rape seeds (Tzen et al. (J. Biol. Chem. 267, 15626-15634).

10

### 2.3 Colour enhancers

The benefit agent can be an agent used to replenish colour on garments. These can be dye molecules or, more preferable, dye molecules incorporated into "packages" or vesicles enabling larger deposits of colour.

15

### 2.4 Fabric regenerating agents

The benefit agent can be an agent able to regenerate damaged fabric. For example, enzymes able to synthesise cellulose fibres could be used to build and repair damaged fibres on the garment.

20

### 2.5 Others

A host of other agents could be envisaged to impart a benefit to fabric. These will be apparent to those skilled in the art and will depend on the benefit being captured at the fabric surface. Examples of softening agents are clays, cationic surfactants or silicon compounds. Examples of finishing agents/protective agents are polymeric lubricants, soil repelling agents, soil release agents, photo-protective agents (sunscreens), anti-static agents, dye-fixing agents, anti-bacterial agents and anti-fungal agents.

30

### 3.1 The fabrics

For laundry detergent applications, several classes of natural or man-made fabrics can be envisaged, in

35

particular cotton. Such macromolecular compounds have the advantage that they can have a more immunogenic nature, i.e. that it is easier to raise antibodies against them. Furthermore, they are more accessible at the surface of the fabric than for instance coloured substances in stains, which generally have a low molecular weight.

An important embodiment of the invention is to use a binding molecule (as described above) that binds to several different types of fabrics. This would have the advantage of enabling a single benefit agent to be deposited to several different types of fabric.

The invention can be applied in otherwise conventional detergent compositions for washing fabrics as well in rinse compositions. The invention will now be further illustrated by the following, non-limiting examples.

### Example 1

Scavenging glucose oxidase from solution using an activated surface

#### 1.1 Preparation of a double-headed antibody fragment

##### 1.1.1 Materials for construction of expression vectors

##### 1.1.1.1 Plasmids

Five different (pUC derived) plasmids were used as starting material (for nucleotide sequences, see Figure 1).

- a) pUC.Fv4715-myc
- b) pUC.scFv4715-myc
- c) pUC.Fv3299-H2t
- d) pUC.Fv3418
- e) pUR.4124

All cloning steps were performed in *E.coli* JM109 (endA1, recA1, gyrA96, thi, hsdR17(r<sub>K</sub><sup>-</sup>, m<sub>K</sub><sup>+</sup>), relA1, supE44,  $\square$  (lac-proAB), [F', traD36, proAB, lacI<sup>q</sup>Z $\square$ M15]).

*E.coli* cultures were grown in 2xTY medium (where indicated supplemented with 2% glucose and/or 100 $\mu$ g/ml

ampicillin), unless otherwise indicated. Transformations were plated out on SOBAG plates.

#### 1.1.1.2 Buffers and media

- 5 PBS 0.24g  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$   
0.49g  $\text{Na}_2\text{HPO}_4$  anhydrous  
4.25g NaCl  
make up to 1 litre in  $\text{H}_2\text{O}$  (pH=7.1)
- PBS-T PBS + 0.15% Tween
- 10 2xTY Medium 17g Bacto-tryptone  
10g Bacto-yeast Extract  
5g NaCl  
Make up to 1 liter with distilled water and autoclave.
- 15 2xTY/Amp/Glucose 2xTY + 100 $\mu\text{g}/\text{mL}$  Ampicillin + 1% Glucose  
M9P + Yeast 12g  $\text{Na}_2\text{HPO}_4$ , 6g  $\text{KH}_2\text{PO}_4$ , 0.5g NaCl, 5g  $\text{NH}_4\text{Cl}$ ,  
0.06g L-Proline, 20g Glycerol, 2mL  
Haemin. Make up to 1 liter with distilled  
water and autoclave. Before use add 12.5  
20 mL 10% Yeast extract, 2.5mL 0.01%  
Thiamin, 500 $\mu\text{L}$  1M  $\text{MgCl}_2$ , 25 $\mu\text{L}$  1M  $\text{CaCl}_2$ .
- SOBAG agar 20g Bacto-tryptone  
5g yeast extract  
15g agar  
25 0.5g NaCl  
Make up to 1 litre with distilled water and autoclave.  
Allow to cool and add: 10mL 1M  $\text{MgCl}_2$ , 27.8mL  
2M Glucose, 100 $\mu\text{g}/\text{mL}$  ampicillin.

#### 30 1.1.1.3 Oligonucleotides and PCR

- The oligonucleotide primers used in the PCR reactions were synthesized on an Applied Biosystems 381A DNA Synthesiser by the phosphoramidite method. The primary structures of the oligonucleotide primers used in the  
35 construction of the bispecific 'pGOSA' constructs are shown in Table 1 below.

Nucleotide sequence of the oligonucleotides used to produce the constructs described

DBL.1	5'	CAC CAT CTC CAG AGA CAA TGG CAA G
DBL.2	5'	GAG CGC GAG CTC <u>GGC CGA ACC GGC</u> C <sup>1</sup> GA TCC GCC ACC GCC AGA GCC
DBL.3	5'	CAG GAT <u>CCG GCC GGT TCG GCC</u> <sup>1</sup> CAG GTC CAG CTG CAA CAG TCA GGA
DBL.4	5'	CTA CAT <u>GAA TTC</u> <sup>2</sup> <u>GCT AGC</u> <sup>3</sup> TTA TTA TGA GGA GAC GGT GAC <u>GGT GGT CCC TTG</u> GC
DBL.5	5'	TAA TAA <u>GCT AGC</u> <sup>3</sup> GGA GCT GCA TGC AAA TTC TAT TTC
DBL.6	5'	ACC AAG <u>CTC GAG</u> <sup>4</sup> ATC AAA CGG GG
DBL.7	5'	AAT GTC <u>GAA TTC</u> <sup>2</sup> <u>GTC GAC</u> <sup>5</sup> TCC GCC ACC GCC AGA GCC
DBL.8	5'	ATT GGA <u>GTC GAC</u> <sup>5</sup> ATC GAA CTC ACT CAG TCT CCA TTC TCC
DBL.9	5'	TGA AGT <u>GAA TTC</u> <sup>2</sup> <u>GCG GCC GC</u> <sup>6</sup> T TAT TAC CGT TTG ATT TCG <u>AGC TTG GTC</u> CC
DBL.10	5'	CGA ATT <u>CGG TCA CC</u> <sup>8</sup> G TCT CCT CAC AGG TCC AGT TGC AAC AG
DBL.11	5'	CGA ATT <u>CTC GAG</u> <sup>4</sup> ATC AAA CGG GAC ATC GAA CTC ACT CAG <u>TCT CC</u>
DBL.12	5'	CGA ATT <u>CGG TCA CC</u> <sup>8</sup> G TCT CCT CAC AGG TGC AGT TGC AGG AG
PCR.51	5'	AGG T(C/G) (A/C) A(C/A) <u>C TGC AG</u> <sup>7</sup> (C/G) AGT C(A/T)G G
PCR.89	5'	TGA GGA GAC <u>GGT GAC C</u> <sup>8</sup> GT GGT CCC TTG GCC CC
PCR.90	5'	GAC ATT <u>GAG CTC</u> <sup>9</sup> ACC CAG TCT CCA
PCR.116	5'	GTT AGA <u>TCT CGA G</u> <sup>4</sup> CT TGG TCC C

5

Restriction sites encoded by these primers are underlined.

1=SfiI, 2=EcoRI, 3=NheI, 4=XhoI, 5=SalI, 6=NotI, 7=PstI,

8=BstEII, 9=SacI

The reaction mixture used for amplification of DNA fragments was: 10 mM Tris-HCl, pH8.3/2.5 mM MgCl<sub>2</sub>/50 mM KCl/0.01% gelatin (w/v)/0.1% Triton X-100/400 mM of each dNTP/5.0 units of DNA polymerase/500 ng of each primer (for 100 µl reactions) plus 100 ng of template DNA. Reaction conditions were: 94°C for 4 minutes, followed by 33 cycles of 1 minute at 94°C, 1 minute at 55°C and 1 minute at 72°C.

1.1.2 Plasmid DNA \ Vector \ Insert preparation and ligation \ transformation

Plasmid DNA was prepared using the 'Qiagen P-100 Midi-DNA Preparation' system. Vectors and inserts were prepared by digestion of 10 µg (for vector preparation) or 20 µg (for insert preparation) with the specified restriction endonucleases under appropriate conditions (buffers and temperatures as specified by suppliers). Modification of the DNA ends with Klenow DNA polymerase and dephosphorylation with Calf Intestine Phosphorylase were performed according to the manufacturers instructions. Vector DNA and inserts were separated by agarose gel electrophoresis and purified with DEAE-membranes NA45 (Schleicher & Schnell) as described by Maniatis et al. Ligations were performed in 20 µl volumes containing:

30 mM Tris-HCl pH7.8  
10 mM MgCl<sub>2</sub>  
10 mM DTT  
1 mM ATP  
300-400 ng vector DNA  
100-200 ng insert DNA  
1 Weiss unit T<sub>4</sub> DNA ligase.

After ligation for 2-4 h at room temperature, CaCl<sub>2</sub> competent *E. coli* JM109 were transformed using 7.5 µl ligation reaction. The transformation mixtures were plated onto SOBAG plates and grown overnight at 37°C. Correct clones were identified by restriction analysis and verified by automated dideoxy sequencing (Applied Biosystems).

### 1.1.3 Restriction digestion of PCR products

Following amplification each reaction was checked for the presence of a band of the appropriate size by agarose gel electrophoresis. One or two 100 µl PCR reaction mixtures of each of the PCR reactions PCR.I - PCR.X, together containing approximately 2-4 µg DNA product were subjected to phenol-chloroform extraction, chloroform extraction and ethanol precipitation. The DNA pellets were washed twice with 70% ethanol and allowed to dry. Next, the PCR products were digested overnight (18 h) in the presence of excess restriction enzyme in the following mixes at the specified temperatures and volumes.

15 PCR.I: 50 mM Tris-HCl pH 8.0, 10 mM MgCl<sub>2</sub>, 50 mM NaCl, 4 mM spermidine, 0.4µg/ml BSA, 4 µl (= 40 U) SacI, 4 µl (= 40 U) BstEII, in 100 µl total volume at 37°C.

PCR.II: 10 mM Tris-Acetate pH 7.5, 10 mM MgAc<sub>2</sub>, 50 mM KAc (1x "One-Phor-All" buffer {Pharmacia}), 4 µl (= 48 U) SfiI, in 50 µl total volume at 50°C under mineral oil.

20 PCR.III: 10 mM Tris-Acetate pH 7.5, 10 mM MgAc<sub>2</sub>, 50 mM KAc (1x "One-Phor-All" buffer {Pharmacia}), 4 µl (= 40 U) NheI, 4 µl (= 40 U) SacI, in 100 µl total volume at 37°C.

25 PCR.IV: 20 mM Tris-Acetate pH 7.5, 20 mM MgAc<sub>2</sub>, 100 mM KAc (2x "One-Phor-All" buffer {Pharmacia}), 4µl (= 40 U) XhoI, 4 µl (= 40 U) EcoRI, in 100 µl total volume at 37°C.

30 PCR.V: 20 mM Tris-Acetate pH 7.5, 20 mM MgAc<sub>2</sub>, 100 mM KAc (2x "One-Phor-All" buffer {Pharmacia}), 4 µl (= 40 U) SalI, 4 µl (= 40 U) EcoRI, in 100 µl total volume at 37°C.

35 PCR.VI: 10 mM Tris-Acetate pH 7.5, 10 mM MgAc<sub>2</sub>, 50 mM KAc (1x "One-Phor-All" buffer {Pharmacia}), 4 µl (= 48 U) SfiI, in 50 µl total volume at 50°C under mineral

oil.

PCR.VII: 50 mM Tris-HCl, pH 8.0, 10 mM MgCl<sub>2</sub>, 50 mM NaCl, 4 mM spermidine, 0.4 µg/ml BSA, 4 µl (= 40 U) NheI, 4 µl (= 40 U) BstEII, in 100 µl total volume at 37°C.

5 PCR.VIII: 20 mM Tris-Acetate pH 7.5, 20 mM MgAc<sub>2</sub>, 100 mM KAc (2x "One-Phor-All" buffer {Pharmacia}), 4 µl (= 40 U) EcoRI, in 50 µl total volume at 37°C.

PCR.IX: 25 mM Tris-Acetate, pH 7.8, 100 mM KAc, 10 mM MgAc, 1 mM DTT (1x "Multi-Core" buffer {Promega}), 4 mM spermidine, 0.4 µg/ml BSA, 4 µl (= 40 U) NheI, 4 µl (= 40 U) BstEII, in 100 µl total volume at 37°C.

PCR.X: 50 mM Tris-HCl, pH 8.0, 10 mM MgCl<sub>2</sub>, 50 mM NaCl, 4 mM spermidine, 0.4 µg/ml BSA, 4 µl (= 40 U) PstI, 4 µl (= 40 U) EcoRI, in 100 µl total volume at 37°C.

15

After overnight digestion, PCR.II-SfiI was digested with EcoRI (overnight at 37°C) by the addition of 16 µl H<sub>2</sub>O, 30 µl 10x "One-Phor-All" buffer (Pharmacia) (100 mM Tris-Acetate pH 7.5, 100 mM MgAc<sub>2</sub>, 500 mM KAc) and 4 µl (= 40 U) EcoRI. After overnight digestion, PCR.VI-SfiI was digested with NheI (overnight at 37°C) by the addition of 41 µl H<sub>2</sub>O, 5 µl 10x "One-Phor-All" buffer (Pharmacia) (100 mM Tris-Acetate pH 7.5, 100 mM MgAc<sub>2</sub>, 500 mM KAc) and 4 µl (= 40 U) NheI. After overnight digestion, PCR.VIII-EcoRI was digested with XhoI (overnight at 37°C) by the addition of 46 µl H<sub>2</sub>O and 4 µl (= 40 U) XhoI.

The digested PCR fragments PCR.I-SacI/BstEII, PCR.II-SfiI/EcoRI, PCR.III-NheI/SacI, PCR.IV-XhoI/EcoRI, PCR.V-SalI/EcoRI, PCR.VI-SfiI/NheI, PCR.VII-BstEII/NheI and PCR.VIII-XhoI/EcoRI were purified on an 1.2% agarose gel using DEAE-membranes NA45 (Schleicher & Schnell) as described by Maniatis et al. The purified fragments were dissolved in H<sub>2</sub>O at a concentration of 100-150 ng/µl.

35 1.1.4 Construction of the pGOSA Double-Head expression vectors

The expression vectors used were derivatives of pUC.19 containing a HindIII-EcoRI fragment that in the case of the scFvs contains one pelB signal sequence fused to the 5' end of the heavy chain V-domain that is directly linked to the corresponding light chain V-domain of the antibody through a connecting sequence that codes for a flexible peptide (Gly<sub>4</sub>Ser)<sub>3</sub> thus generating a single-chain molecule. In the dual-chain Fv expression vector both the heavy chain and the light chain V-domains of the antibody are preceded by a ribosome binding site and a pelB signal sequence in an artificial dicistronic operon under the control of a single inducible promoter. Expression of these constructs is driven by the inducible lacZ promoter. The nucleotide sequence of the HindIII-EcoRI inserts of the Fv.3418, Fv.4715-myc, scFv.4715-myc and pUR.4124 constructs used for the generation of the bispecific antibody fragments are listed in Figure 1.

The construction of pGOSA.E involved several cloning steps that produced 4 intermediate constructs pGOSA.A to pGOSA.D. The final expression vector pGOSA.E and the oligonucleotides in Table.1 have been designed to allow most specificities to be cloned into the final pGOSA.E construct. The upstream VH domain can be replaced by any PstI-BstEII VH gene fragment obtained with oligonucleotides PCR.51 and PCR.89. The oligonucleotides DBL.3 and DBL.4 were designed to introduce SfiI and NheI restriction sites in the VH gene fragments thus allowing cloning of those VH gene fragments into the SfiI-NheI sites as the downstream VH domain. All VL gene fragments obtained with oligonucleotides PCR.116 and PCR.90 can be cloned into the position of the 3418 VL gene fragment as a SacI-XhoI fragment. A complication here however is the presence of an internal SacI site in the 3418 VH gene fragment. Oligonucleotides DBL.8 and DBL.9 are designed to allow cloning of VL gene fragments into the position of the 4715 VL gene fragment as a SalI-NotI fragment. The pGOSA.E derivatives pGOSA.V, pGOSA.S and pGOSA.T with only one or no linker sequences contain some aberrant restriction sites at



the new joining points. The  $VH_A$ - $VH_B$  construct without a linker lacks the 5' $VH_B$  SfiI site. The  $VH_B$  fragment is cloned into these constructs as a BstEII/NheI fragment using oligonucleotides DBL.10 or DBL.11 and DBL.4. The  $VL_B$ - $VL_A$  construct without a linker lacks the 5' $VL_A$  SalI site. The  $VL_A$  fragment is cloned into these constructs as a XhoI/EcoRI fragment using oligonucleotides DBL.11 and DBL.9.

pGOSA.A : This construct was derived from the scFv.4715-myc construct. A SfiI restriction site was introduced between the (Gly<sub>4</sub>Ser)<sub>3</sub> linker and the gene fragment encoding the VL of the scFv.4715-myc construct. This was achieved by replacing the BstEII-SacI fragment of this construct by the fragment PCR-I BstEII/SacI that contains a SfiI site between the (Gly<sub>4</sub>Ser)<sub>3</sub> linker and the 4715 VL. The introduction of the SfiI site also introduced 4 additional amino acids (Ala-Gly-Ser-Ala) between the (Gly<sub>4</sub>Ser)<sub>3</sub> linker and the 4715 VL gene fragment. The oligonucleotides used to produce PCR-I (DBL.1 and DBL.2) were designed to match the sequence of the framework-3 region of the 4715 VH and to prime at the junction of the (Gly<sub>4</sub>Ser)<sub>3</sub> linker and the gene encoding the 4715 VL respectively (Table 1).

pGOSA.B : This construct was derived from the Fv.3418 construct. The XhoI-EcoRI fragment of Fv.3418 encoding the 3' end of framework-4 of the VL including the stop codon was removed and replaced by the fragment PCR-IV XhoI/EcoRI. The oligonucleotides used to produce PCR-IV (DBL.6 and DBL.7) were designed to match the sequence at the junction of the VL and the (Gly<sub>4</sub>Ser)<sub>3</sub> linker perfectly (DBL.6), and to be able to prime at the junction of the (Gly<sub>4</sub>Ser)<sub>3</sub> linker and the VH in pUR.4124 (DBL.7) (Table 1). DBL.7 removed the PstI site in the VH (silent mutation) and introduced a SalI restriction site at the junction of the (Gly<sub>4</sub>Ser)<sub>3</sub> linker and the VH, thereby replacing the last Ser of the linker by a Val residue.

pGOSA.C : This construct contained the 4715 VH linked by the (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker to the 3418 VH. This construct was obtained by replacing the SfiI-EcoRI fragment  
5 from pGOSA.A encoding the 4715 VL by the fragment PCR-II SfiI/EcoRI encoding the 3418 VH. The oligonucleotides used to produce PCR-II (DBL.3 and DBL.4) (Table 1) hybridize in the framework-1 and framework-4 region of the gene encoding the 3418 VH respectively. DBL.3 was designed to remove the PstI  
10 restriction site (silent mutation) and to introduce a SfiI restriction site upstream of the VH gene. DBL.4 destroys the BstEII restriction site in the framework-4 region and introduces a NheI restriction site downstream of the stopcodons.

15

pGOSA.D : This construct contained a dicistronic operon consisting of the 3418 VH and the 3418 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the 4715 VL. This construct was obtained by digesting the pGOSA.A construct with SalI-EcoRI  
20 and inserting the fragment PCR-V SalI/EcoRI containing the 4715 VL. The oligonucleotides used to obtain PCR-V (DBL.8 and DBL.9) (Table 1) were designed to match the nucleotide sequence of the framework-1 and framework-4 regions of the 4715 VL gene respectively. DBL.8 removed the SacI site from  
25 the framework-1 region (silent mutation) and introduced a SalI restriction site upstream of the VL chain gene. DBL.9 destroyed the XhoI restriction site in the framework 4 region of the VL (silent mutation) and introduced a NotI and a EcoRI restriction site downstream of the stop codons.

30

pGOSA.E : This construct contained a dicistronic operon consisting of the the 4715 VH linked by the (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker to the 3418 VH plus the 3418 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the 4715 VL. Both  
35 translational units are preceded by a ribosome binding site and a pelB leader sequence. This construct was obtained by a

three-point ligation by mixing the pGOSA.D vector from which the PstI-SacI insert was removed, with the PstI-NheI pGOSA.C insert and the fragment PCR-III NheI/SacI. The PstI-SacI pGOSA.D vector contains the 5' end of the framework-1 region of the 3418 VH upto the PstI restriction site and the 3418 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the 4715 VL starting from the SacI restriction site in the 3418 VL. The PstI-NheI pGOSA.C insert contains the 4715 VH linked by the (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker to the 3418 VH, starting from the PstI restriction site in the framework-1 region in the 4715 VH. The NheI-SacI PCR-III fragment provides the ribosome binding site and the pelB leader sequence for the 3418 VL-(Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val-4715 VL construct. The oligonucleotides DBL.5 and PCR.116 (Table 1) used to generate PCR-III were designed to match the sequence upstream of the ribosome binding site of the 4715 VL in Fv.4715 and to introduce a NheI restriction site (DBL.5), and to match the framework-4 region of the 3418 VL (PCR.116).

20 pGOSA.G : This construct was an intermediate for the synthesis of pGOSA.J. It is derived from pGOSA.E from which the VH4715 PstI/BstEII fragment has been excised and replaced by the VH3418 PstI/BstEII fragment (excised from Fv.3418). The resulting plasmid pGOSA.G contains two copies of the 3418 Heavy chain V-domain linked by the (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker, plus the 4715 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the framework 4 region of the 3418 VL.

pGOSA.J : This construct contained a dicistronic operon consisting of the 3418 VH linked by the (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker to the 4715 VH plus the 3418 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the 4715 VL. Both transcriptional units are preceded by a ribosome binding site and a pelB leader sequence. This construct was obtained by inserting the fragment PCR-VI SfiI/NheI which contains the VH4715, into the vector pGOSA.G from which the SfiI/NheI VH3418 which was

removed.

5     pGOSA.L : This construct was derived from pGOSA.E from which  
the HindIII/NheI fragment containing the 4715 VH-  
(Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala-3418 VH encoding gene was removed.  
The DNA ends of the vector were made blunt-end using Klenow  
DNA polymerase and ligated. The resulting plasmid pGOSA.L  
contains the 3418 VL domain linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val  
linker to the 5' end of the framework 1 region of the 4715 VL  
10    domain.

15    pGOSA.V : This construct was derived from pGOSA.E from which  
the VH3418-(Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker BstEII/NheI  
fragment has been excised and replaced by the fragment PCR-  
VII BstEII/NheI which contains the 3418 VH. The resulting  
plasmid pGOSA.V contains the 3418 Heavy chain V-domain linked  
directly to the framework 4 region of the 4715 VH, plus the  
4715 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the  
framework 4 region of the 3418 VL.

20    pGOSA.S : This construct was derived from pGOSA.E from which  
the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val-VL4715 XhoI/EcoRI fragment has been  
excised and replaced by the fragment PCR-VIII XhoI/EcoRI  
which contains the 4715 VL. The resulting plasmid pGOSA.S  
25    contains the 4715 VH linked by the (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala  
linker to the 3418 VH plus the 3418 VL linked directly to the  
5' end of the framework 1 region of the 4715 VL.

30    pGOSA.T : This construct contained a dicistronic operon  
consisting of the 3418 Heavy chain V-domain linked directly  
to the framework 4 region of the 4715 VH plus the 3418 VL  
linked directly to the 5' end of the framework 1 region of  
the 4715 VL. Both transcriptional units are preceded by a  
ribosome binding site and a pelB leader sequence. This  
35    construct was obtained by inserting the NheI/EcoRI fragment  
of pGOSA.S which contains the 3418 VL linked directly to the

5'end of the framework 1 region of the 4715 VL, into the vector pGOSA.V from which the NheI/EcoRI fragment containing the 3418 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the 4715 VL was removed.

5

pGOSA.X : This construct was derived from pGOSA.T from which the NheI/EcoRI fragment containing the 3418 VL-4715 VL encoding gene was removed. The DNA ends of the vector were made blunt-end (Klenow) and ligated. The resulting plasmid  
10 pGOSA.X contains the 4715 VH domain linked directly to 5'end of the framework 1 region of the 3418 VH domain.

pGOSA.Y : This construct was derived from pGOSA.T from which the HindIII/NheI fragment containing the 4715 VH-3418 VH  
15 encoding gene was removed. The DNA ends of the vector were made blunt-end using Klenow DNA polymerase and ligated. The resulting plasmid pGOSA.Y contains the 3418 VL domain linked directly to 5' end of the framework 1 region of the 4715 VL domain.

20

pGOSA.Z : This construct was derived from pGOSA.G from which the VH3418-(Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker BstEII/NheI fragment has been excised and replaced by the fragment PCR-IX BstEII/NheI which contains the 4715 VH. The resulting plasmid  
25 pGOSA.Z contains the 3418 Heavy chain V-domain linked directly to the framework 1 region of the 4715 VH, plus the 4715 VL linked by the (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the framework 4 region of the 3418 VL.

30 pGOSA.AA : This construct contained a dicistronic operon consisting of the 3418 Heavy chain V-domain linked directly to the 5' end of the framework 1 region of the 4715 VH plus the 3418 VL linked directly to the 5' end of the framework 1 region of the 4715 VL. Both transcriptional units are  
35 preceded by a ribosome binding site and a pelB leader sequence. This construct was obtained by inserting the

NheI/EcoRI fragment of pGOSA.T which contains the 3418 VL linked directly to the 5' end of the framework 1 region of the 4715 VL, into the vector pGOSA.Z from which the NheI/EcoRI fragment containing the 3418 VL linked by the  
5 (Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val linker to the 4715 VL was removed.

pGOSA.AB : This construct was derived from pGOSA.J by a three point ligation reaction. The SacI/EcoRI insert, containing part of the 3418 VH and the full (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker-4715 VH and the 3418 VL-(Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val-4715 VL  
10 encoding sequences was removed and replaced by the SacI/SacI pGOSA.J fragment containing part of the 3418 VH and the full (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker-4715 VH and the SacI/EcoRI pGOSA.T fragment containing the 3418 VL linked directly to  
15 the framework 1 region of the 4715 VL. The resulting plasmid contains the 3418 VH linked by the (Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala linker to the 5' end of the framework 1 region of the 4715 VH plus the 3418 VL linked directly to the 5' end of the framework 1 region of the 4715 VL.

20

pGOSA.AC : This construct was derived from pGOSA.Z from which the NheI/EcoRI fragment containing the 3418 VL-(Gly<sub>4</sub>Ser)<sub>2</sub>Gly<sub>4</sub>Val-4715 VL encoding gene was removed. The DNA ends of the vector were made blunt-end using Klenow DNA  
25 polymerase and ligated. The resulting plasmid pGOSA.AC contains the 3418 VH domain linked directly to 5' end of the framework 1 region of the 4715 VH domain.

pGOSA.AD : This construct was obtained by inserting the  
30 PstI/EcoRI PCR.X fragment containing the 3418 VH-(Gly<sub>4</sub>Ser)<sub>3</sub>Ala-Gly-Ser-Ala-4715 VH encoding gene fragment into the Fv.4715-myc vector from which the PstI/EcoRI Fv.4715-myc insert was removed.

35 1.1.5 Construction of the pAlphagox Double-Head expression vectors

The expression vectors used were derivatives of pGOSA.E,S,T and V in which the heavy chain and the light chain V-domains of the antibody were preceded by a ribosome binding site and a pelB signal sequence in an artificial dicistronic operon under the control of a single inducible promoter. The inducible lacZ promoter drove expression of these constructs.

pAlphagox.A : This construct was derived from pGOSA.E from which the PstI/BstEII 4715 VH gene fragment was removed and replaced by the PstI/BstEII 3299 VH gene fragment from pUC.Fv3299H2t.

pAlphagox.B : This construct was derived from pGOSA.V from which the PstI/BstEII 4715 VH gene fragment was removed and replaced by the PstI/BstEII 3299 VH gene fragment from pUC.Fv3299H2t.

pAlphagox.C : This construct was derived from pAlphagox.A from which the SalI/EcoRI 4715 VL gene fragment was removed and replaced by the SalI/EcoRI 3299 VL equivalent of PCR.V

pAlphagox.D : This construct was derived from pAlphagox.B from which the SalI/EcoRI 4715 VL gene fragment was removed and replaced by the SalI/EcoRI 3299 VL equivalent of PCR.V

pAlphagox.E : This construct was derived from pAlphagox.A from which the XhoI/EcoRI 4715 VL gene fragment was removed and replaced by the XhoI/EcoRI 3299 VL equivalent of PCR.VII

pAlphagox.F : This construct was derived from pAlphagox.B from which the XhoI/EcoRI 4715 VL gene fragment was removed and replaced by the XhoI/EcoRI 3299 VL equivalent of PCR.VII

1.1.6 Expression of GOSA and ALPHAGOX constructs in E.coli

Although the following protocol describes the production of 500mL supernatant and 2x100 mL periplasmic extract this protocol can easily be scaled up.

- 1) Inoculate 2.5 mL 2xTY/Amp with an individual well-isolated colony from a plate with freshly transformed JM109.  
Incubate o/n at 37°C with shaking at 200 rpm.
- 2) Plate out 100 µL aliquots of  $10^{-3}$ ,  $10^{-4}$ ,  $10^{-5}$ , and  $10^{-6}$  dilutions of the o/n culture on 2TY/Amp plates.
- 3) After o/n incubation at 37°C two types of colonies are usually visible; small 'Creamy' and large 'Grey' types.
- 4) Set up starter cultures of both 'creamy' and 'grey' colony types in 10 mL BHI/Amp o/n 37°C (no shaking).
- 5) 5 mL of the o/n starter cultures is used to inoculate 500 mL M9P+Yeast medium.
- 6) The culture is grown at 25°C with shaking at 150-200 rpm (in baffled flasks) until  $OD_{600}=0.6-1.0$ .
- 7) IPTG is added to a final concentration of 1mM.
- 8) Incubate the culture overnight at 25°C with shaking at 150-200 rpm.
- 9) Centrifuge the overnight culture and test the supernatant for the presence of antibody fragment.
- 10) The product present in the periplasmic space can be extracted by two consecutive osmotic shock lysis.

## 1.2 Activating a Surface with a Double-headed Antibody Fragment

- A 50 µg/ml solution of human chorionic gonadotrophin (hCG) was made up in phosphate buffered saline (PBS) and 100 µl was added per well of a Greiner HB microtitre plate.
- Following a 60 minute incubation at room temperature with constant agitation the wells were washed three times with 200 µl PBS containing 0.15 % (v/v) Tween 20 (PBST). The wells were then blocked by a 60 minute incubation with 1% (w/v) Marvel at room temperature. The surface was activated by a 30 minute incubation with 0.25 µg/well of double head (alphagox)



in a PBS solution pH adjusted to 8.0. Following activation of the surface each well was washed three times with 200  $\mu$ l PBST.

5    1.3 Scavenging Glucose Oxidase from a Solution

A solution of glucose oxidase (100  $\mu$ l of a 60  $\mu$ g/ml solution made up in PBS) was incubated for 60 minutes at room temperature with gentle agitation. During this time the glucose oxidase was captured at the activated surface.

10 Following the capture of glucose oxidase at the activated surface each well was washed three times with 200  $\mu$ l PBST. The presence of captured glucose oxidase was revealed by incubation with a substrate solution comprising; 50 mM glucose, 5  $\mu$ l of peroxidase (Novo) at 21.8 mg/ml, 200  $\mu$ l TMB  
15 made up to 20 ml with PBS at pH 8.0. After 10 minutes 50  $\mu$ l of HCl (1 M) was added and the optical density of the ELISA plate was read at 450 nm. Figure 6 shows that an activated surface can capture glucose oxidase (A, hCG then Bi-head then glucose oxidase; B, hCG then glucose oxidase; C, no hCG then  
20 Bi-head then glucose oxidase).

Example 2

Scavenging glucose oxidase from solution onto red wine activated plastic

25

2.1 Preparation of a Bi-headed Antibody Fragment

A bi-headed antibody fragment (12.49) with dual specificity for red wine and glucose oxidase was constructed, produced and purified as follows:

30

2.1.1 Preparation of a red wine specific heavy chain immunoglobulin fragment from llama

2.1.1.1 Antigen Preparation

35

Cote du Rhone red wine (Co-op) was filtered through a

0.2µ membrane and then used either neat or diluted in PBS as appropriate.

#### 2.1.1.2 Immunisation Schedule

5           A llama, kept at the Dutch Institute for Animal  
Science and Health (ID-DLO, Lelystad), was immunised first  
with BSA-red wine linked by periodate chemistry and  
thereafter boosted one month later and then a further two  
months later with red wine conjugated to PLP. Serum was  
10 removed 14 days after each boost for analysis.

#### 2.1.1.3 Polyclonal Sera Analysis

Sera were analysed by ELISA against red wine as follows:

- 15 1. A Greiner HB microtitre plate was sensitised with red wine  
at 37°C and then washed in PBSTA.
2. The plate was blocked by pre-incubating with 200 µl/well  
1% (w/v) ovalbumin in PBSTA for 1 hour at room  
temperature.
- 20 3. Blocking buffer was removed and 100µl/well llama immunised  
sera or prebleed, beginning with a 10<sup>-2</sup> dilution in PBSA,  
added. Incubations were for 1 hour at room temperature.
4. Unbound antibody fragment was removed by washing 3x using  
a plate washer in PBSTA.
- 25 5. 100µl/well of rabbit anti-llama IgG was added at 10µg/ml  
in PBSTA. Incubation was for 45 minutes at room  
temperature.
6. Plate was washed as described in step 4.
7. 100µl/well alkaline phosphatase conjugated goat anti-  
30 rabbit (Sigma) was added at an appropriate dilution in  
PBSTA and incubated for 45 minutes at room temperature.
8. Plate was washed as described previously.
9. Alkaline phosphatase activity was detected by adding  
100µl/well substrate solution: 1mg/ml pNPP in 1M  
35 diethanolamine, 1mM MgCl<sub>2</sub>.

10. Absorbance was read at 405nm when the colour had developed.

#### 2.1.1.4 mRNA Isolation and cDNA synthesis

5             $4 \times 10^8$  PBLs were isolated using a ficoll gradient and total RNA was isolated based on the method of Chomczynski and Sacchi, (1987) Anal. Biochem., 162, 156-159.

mRNA was subsequently prepared using Oligotex mRNA Qiagen Purification kit.

10            cDNA was synthesised using First Strand Synthesis for RT-PCR kit from Amersham (RPN 1266) and the oligo dT primer using approximately 2  $\mu$ g mRNA (1 $\mu$ g/Eppendorf) as estimated from the total RNA concentration and assuming that mRNA constitutes approximately 1% of the total RNA.

15

#### 2.1.1.5 Isolation of short and long-hinge HCVs by PCR

A master mix for the amplification of short and long-hinge PCR was prepared as follows:

46 $\mu$ l dNTP mix (5mM)

20    11.5 $\mu$ l LAM 07 or LAM 08 (100pmol/ $\mu$ l)

LAM 07 3' primer (short hinge)

5' AACAGTTAAGCTTCCGCTTGCGGCCGCGGAGCTGGGGTCTTCGCTGTGGTGCG '3

25    LAM 08 3' primer (long hinge)

5' ACAGTTAAGCTTCCGCTTGCGGCCGCTGGTTGTGGTTTGGTGTCTTGGGTT '3

11.5 $\mu$ l  $V_H$  2B (100pmol/ $\mu$ l)

30     $V_H$  2B 5' primer

5' AGGTSMARCTGCAGSAGTCWGG '3

S = C/G, M = A/C, W = A/T, R = A/G

115 $\mu$ l  $MgCl_2$  (25mM)

161 $\mu$ l dep water

35            20 tubes for both short and long-hinge amplification

- 30 Appropriate ratios of PCR product were combined with digested vector using DNA ligase (Gibco BRL) according to the manufacturer's instructions. Ligation reactions were purified and used to transform electrocompetent *E. coli* XL-1 Blue (Stratagene).

#### 2.1.1.8 Phage Rescue Maxiscale

15ml 16 g Tryptone, 10 g Yeast extract, 5 g NaCl per litre containing 2 % glucose and 100 ug/ml ampicillin (2TY/Amp/Glucose) was inoculated with 100µl of glycerol stock of either short or long-hinge VHH library and phage rescues were performed. The cells were grown until thin log phase was reached and infected with M13K07 helper phage (Gibco BRL). Infected cells were pelleted and resuspended in 2TY/Amp/Kan to allow release of phage into the supernatant. After overnight incubation at 37°C, phage were pelleted and concentrated by PEG precipitation. The final phage pellet was resuspended in 1ml PBS in 2% BSA/1% marvel, or 2% ovalbumin/1% marvel as appropriate, and incubated for approximately 30 minutes at room temperature.

#### 2.1.1.9 Selection of Antigen Binding Phages: Panning

Nunc-immunotubes were sensitised with either 2ml of red wine, or PBSA only (as a negative control) for 1 week at 37°C. The tubes were washed with PBSA and preblocked with 2ml 2% BSA/1% marvel in PBSTA at room temperature for about 3 hours.

Blocking solution was removed and 100µl blocked phage solution in a total volume of 0.075% LAS/CoCo in 2%BSA/1%marvel added to the immunotubes. Samples were incubated for 3.5 hours at room temperature.

The tubes were washed 20x with PBST and 20x with PBS. Bound phage were removed from the surfaces with 0.5ml 0.2M glycine/0.1M HCl pH2.2 containing 10mg/ml BSA, and incubating at room temperature for 15 minutes. The solutions were removed into fresh tubes and neutralised with 30µl 2M Tris. *E. coli* XL-1 Blue were infected with eluted phage.

#### 2.1.1.10 Generation of Soluble HCV Fragments

DNA was isolated from the panned library using Qiagen

mid-prep kit used to transform  $\text{CaCl}_2$  competent *E. coli* D29A1, which were plated out on SOBAG plates and grown overnight at 37°C. Individual colonies of freshly transformed *E. coli* D29A1 were picked and VHH expression induced using  
5 IPTG.

#### 2.1.1.11 Detection of Expression of Anti-Polyphenol VHH-myc Constructs

Greiner microtitre plates were sensitised with  
10 100µl/well red wine, as well as other sources of polyphenols or PBSA only for about 60 hours at 37°C. Plates were blocked with 200µl/well 1% BSA/PBSTA for 1 hour at 37°C. 65µl crude *E. coli* supernatant was pre-mixed with 32µl 2% BSA/PBSTA and added to the appropriate wells of the blocked plates. VHHs  
15 were allowed to bind to the antigens for 2 hours at 37°C. Unbound fragments were removed by washing 4x with PBSTA. 100µl/well of an appropriate dilution of mouse anti-myc antibody in 1% BSA/PBSTA was added and incubated for 1 hour at 37°C. Plates were washed as previously and 100µl/well of  
20 an appropriate dilution of alkaline phosphatase conjugated goat anti-mouse (Jackson) in 1% BSA/PBSTA added and incubated as before. Plates were again washed and alkaline phosphatase activity was detected by adding 100µl/well substrate solution: 1mg/ml pNPP in 1M diethanolamine/1 mM  $\text{MgCl}_2$ . When  
25 the colour had developed an absorbance reading at 405nm was taken.

#### 2.1.2 Preparation of Anti-GOx VHH Fragments

A llama, kept at the Dutch Institute for Animal  
30 Science and Health (ID-DLO, Lelystad) was immunised with equimolar amounts of two different GOx preparations: Novo and Amano.

The llama was immunised and then boosted twice more,

one month apart, prior to removal of peripheral blood lymphocytes (PBLs) for RNA isolation.

Libraries of short and long-hinge VHs were constructed as described for the red wine VHs above.

- 5 Libraries were panned against immunotubes (Nunc) sensitised with either 2ml of 20µg/ml GOx (Novo) or PBSa only (negative control). DNA from the panned libraries was isolated and used to transform *E. coli* D29A1. Individual colonies were picked and soluble VHH fragments generated exactly as described  
10 above.

#### 2.1.2.1 Detection of Expression of Anti-GOx VHH-myc Constructs.

- High binding capacity microtitre plates (Greiner)  
15 were sensitised with 100µl/well either 10µg/ml GOx (Novo) or PBSa only overnight at 37°C. Plates were blocked with 200µl/well 1% BSA/PBSTA for 1 hour at 37°C. 80µl crude *E. coli* supernatant was pre-mixed with 40µl 2% BSA/PBSTA and added to the appropriate wells of the blocked plates. VHs  
20 were allowed to bind for 2 hours at 37°C. Binding of VHs to GOx was detected as described for the VHs binding to red wine.

#### 2.1.3 Construction of RW/GOx Bi-Head Expression Vectors

- 25 The strategy for cloning of bi-head molecules is shown diagrammatically in Figure 7.

##### 2.1.3.1 PCR of VHH49RW

- HCV49RW was PCR amplified using primers 51 and HCV 3'  
30

##### Primer 51

5' AGGTCAAAGTGCAGCAGTCAGG

GC G G T

##### HCV 3'

- 35 5' TCCTGAGGAGACGGTGACCTGGGTCCCCTG '3

The reaction mixture for amplification was 10pmoles each primer, 1xPfu buffer (Stratagene), 0.2mM dNTPs, 0.2µl VHH49RW midiprep DNA, 1µl Pfu enzyme (Stratagene), water to 50µl. The  
5 reaction conditions were:  
94°C for 4mins  
94°C for 1min       }  
55°C for 1min       } 33 cycles  
72°C for 1min       }  
10 72°C for 10mins

#### 2.1.3.2 Cloning of VHHs into pPic Yeast Expression Vector

VHH12GOx was excised from the plasmid pUR4536 using PstI and BstEII according to the manufacturers instructions.  
15 The PCR fragment of VHH49RW was similarly digested. All excised fragments were purified from a 1% agarose gel using Qiaex II purification kit (Qiagen).

Fragments were then cloned into the modified vector, pUC19 (containing an XhoI restriction site at the 5' end of a  
20 previously cloned VHH and a hydrophil II tail for detection), which had also been digested with PstI and BstEII. Ligation was performed using DNA ligase (Gibco BRL) according to the manufacturers instructions. Calcium chloride competent *E. coli* TG1 were transformed with a portion of the ligation  
25 reaction. To select clones containing the correct inserts, single colonies were picked, DNA isolated, and diagnostic restriction enzyme analysis performed using PstI and BstEII. To verify the inserts, DNA was sequenced by automated dideoxy sequencing (Applied Biosystems).

30 VHHs were subsequently excised from the pUC19 vectors using sequential digests with XhoI and EcoRI and the buffers recommended by the enzyme manufacturers. pPic9 vector (Invitrogen) was similarly digested and the digested VHHs inserted into this vector as described for cloning into  
35 pUC19. Clones containing the correct inserts were again



determined using diagnostic digests with XhoI and EcoRI, and DNA sequencing.

To create the bi-head constructs the anti-polyphenol VHH49RW and the anti-GOx VHH12GOx were combined in the same pPic9 DNA vector. pPic9 vector containing anti-GOx VHH was digested with BstEII and EcoRI to remove an 85bp fragment. pPic9 vector containing VHH49RW was digested with PstI and EcoRI to release the VHH. All restriction enzyme digestions were sequential using appropriate buffers as recommended by the manufacturers. Digested vector and VHH were purified using Qiaex II purification kit (Qiagen).

Two oligonucleotides, containing a 5' BstEII and a 3' PstI overhang (GTCACCGT CTCCTCACAGGTGCAGCTGCA, and GCAGAGGAGTGTCCACGTCG) were annealed using the following mix:

1µg each oligonucleotide  
1µl 10x ligase buffer (Promega)  
water to 10µl.

The mix was boiled for 1 minute and then allowed to cool over approximately 30 minutes. 190µl water was added. Different ratios of VHH49RW and VHH12Gox containing vector were added. The three-point ligation reactions were performed using the conditions previously described. 100µl calcium chloride competent *E. coli* XL-1Blue was transformed with 4µl ligation reaction. Identification of clones containing both VHHs was performed using primers 392 and 393.

**Primer 392**

5' GCAAATGGCATTCTGACATCC '3

**Primer 393**

5' TACTATTGCCAGCATTGCTGC '3

Amplified DNA was analysed on a 1 % agarose gel and vectors containing bi-heads identified according to size. Appropriate clones were further confirmed by diagnostic

restriction enzyme digests of the PCR products with PstI and BstEII simultaneously, and dideoxy Sanger sequencing using primers 392 and 393. The predicted amino acid sequence of bihead 12.49 is shown in Figure 8.

5

## 2.2 Expression of Bi-Heads in *Pichia pastoris*

pPic9 vectors containing bi-head DNA was transformed into the methylotrophic yeast, *Pichia pastoris*. 10µg vector DNA was digested with the DNA restriction enzyme Bgl II, purified by phenol extraction, ethanol precipitated, and used to transform electrocompetent *P. pastoris* strain GS115 (Invitrogen). Cells were grown for 48 hours at 30°C on MD plates (1.34% TND, 5x10<sup>-5</sup>% biotin, 0.5% methanol, 0.15% agar) and then Mut<sup>+</sup>/Mut<sup>s</sup> colonies selected by patching on both an MM plate (1.34 % TND, 5x10<sup>-5</sup>% biotin, 1% glucose, 0.15 % agar) and an MD plate. Colonies that grow normally on the MD plates but grow very slowly on the MM plates are the Mut<sup>s</sup> clones.

A single colony from the MD plates was used to inoculate 10ml BMGY medium (1 % yeast extract, 2 % peptone, 100 mM potassium phosphate pH 6.0, 1.34 % YNB, 5x10<sup>-5</sup>% biotin, 1 % glycerol) in a 50ml Falcon tube. Expression of the bi-heads was induced by the addition of methanol after allowing the colonies to reach log phase. Supernatants were harvested by centrifugation and analysed.

25

## 2.3 Activating a Surface with a Bi-headed Antibody Fragement

Red wine was incubated overnight at 37°C on a Nunc microtitre plate at 200 µl/well and plates were then stored at 4°C until required. Plates were washed once with phosphate buffered saline containing 0.15 % (v/v) Tween 20 and 0.02 % thiomersal (PBSTM) and incubated with bi-head 12.49 at various dilutions from a culture supernatant (at a stock concentration of about 1 mg/ml). After 20 minutes the wells of the microtitre plate were washed three times by the

35

addition of 200  $\mu$ l PBSTM.

#### 2.4 Scavenging glucose oxidase from a solution and subsequent detection

5           A solution of glucose oxidase (Novo) was incubated at 100  $\mu$ l/well (20  $\mu$ g/ml diluted in PBSTM) for 15 minutes at room temperature. The wells were then washed three times by the addition of 200  $\mu$ l PBSTM and then incubated with 100  $\mu$ l/well of substrate solution comprising, 20 mM glucose, 10  $\mu$ g/ml tetra methyl benzidine, 1  $\mu$ g/ml horseradish peroxidase  
10           in 0.1 M phosphate buffer at pH 6.5. After 10 minutes 100  $\mu$ l 1 M HCl was added per well and the optical density at 450 nm was determined. For comparison, following the binding of red wine to the microtitre plate a solution, comprising a mixture  
15           of bi-head at various dilutions and glucose oxidase at 20  $\mu$ g/ml diluted in PBSTM, was incubated for 15 minutes and the plate washed as described above. Figure 9 shows that a red wine surface activated with bi-head (Fig 9 A) can scavenge more glucose oxidase than can be bound to a wine surface when  
20           bi-head and glucose oxidase are mixed together in a single step (Fig. 9 B).

#### Example 3

Scavenging glucose oxidase from solution onto red wine  
25           activated cotton

#### 3.1 Activating a Cotton Surface with a Bi-headed Antibody Fragment

30           Cotton sheets (approx. 20 x 10 cm) were stained with red wine by immersion of the sheets in red wine for 2 hours at 37°C. The stained sheets were allowed to air dry at 37°C and then stored in the dark for 4 days in sealed foil bags. Stained sheets were stored in foil bags until required at -20°C. Stained cotton swatches were prepared by punching

circular discs of fabric from the sheets using a hole puncher. Swatches were pre-washed in 0.1 M sodium carbonate buffer pH 9.0 and a Nunc microtitre plate was blocked by incubation of wells with 200  $\mu$ l of 1% (w/v) Marvel. Swatches  
5 were placed in the wells of the microtitre plate and 100  $\mu$ l bi-head 12.49 at 5  $\mu$ g/ml in 0.1 M sodium carbonate buffer pH 9.0 was added per well. After a 15 minute incubation at room temperature the swatches were washed three times with 0.1 M sodium carbonate buffer pH 9.0.

10

### 3.2 Scavenging glucose oxidase from a solution and subsequent bleaching of red wine stain

A solution of glucose oxidase (100  $\mu$ l aliquot at 50  $\mu$ g/ml in 0.1 M sodium carbonate buffer pH 9.0) was incubated with the  
15 activated swatch in the well of a microtitre plate for 15 minutes at 37°C. The swatches were then washed three times in 0.1 M sodium carbonate buffer pH 9.0 and then 25  $\mu$ l of glucose (80 mM) was added to each swatch and incubated at room temperature for 60 minutes. The swatches were washed  
20 with distilled H<sub>2</sub>O five times and then dried at 37°C. Images of the swatches were then scanned on a Hewlet Packard ScanJet ADF digital scanner. For comparison pre-washed swatches which had not been exposed to bi-head were incubated with a mixture of bi-head 12.49 (5  $\mu$ g/ml), glucose oxidase (50  $\mu$ g/ml) and  
25 glucose (80 mM) at room temperature for 60 minutes. These swatches were washed in H<sub>2</sub>O and dried as above. The samples that were pre-activated with binding molecules gave superior bleaching results when compared to untreated ones. This demonstrates the advantage of pre-activating a surface to  
30 capture a benefit agent which can then exert or perform its desired effect at the specified site or region.

#### Example 4

##### The capture of oil bodies on fabric

The experiment exemplifies capture of particles (plant oil bodies) on cotton fabric which has been preprepared with a biorecognition molecule able to bind to cotton and specifically scavenge particles from the surrounding  
5 environment.

#### 1.1 Oil Body Isolation

Oil bodies were isolated from rape seeds essentially as described by Tzen et al. (J. Biol. Chem. 267, 15626-15634).  
10 Briefly rape seeds were ground to a fine powder in liquid nitrogen using a pestle and mortar, and sieved. 1g crushed seed was homogenised in 4g grinding medium, on ice. The sample was mixed with an equal volume of floating medium containing 0.6M sucrose, and centrifuged. The 'fat pad' was  
15 removed to another tube, resuspended in floating medium containing 0.25M sucrose, and centrifuged. The 'fat pad' was collected and stored at 4°C.

#### 1.2 Preparation of Oil Bodies Containing Nile Red

20 In order to be able to visualise the presence of oil bodies on skin or cotton, they were prepared containing the lipophilic reagent, nile red, which is a fluorescent label.

A crystal of nile red was added to a 2% suspension of oil  
25 bodies in water. The sample was vortexed for 2 minutes and centrifuged at 13,000rpm for 2 minutes. The upper layer containing the oil bodies was removed and washed with phosphate buffered saline (PBS) (0.24g  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ , 0.49g  $\text{Na}_2\text{HPO}_4$  anhydrous, 4.25g NaCl, in 1L water, pH7.1) 3 times.  
30 After the final wash, the oil bodies were resuspended in 5ml PBS.

#### 1.3 Sensitisation of Oil Bodies with Reactive Red 6 and Nile Red

35 An antibody to the azo-dye reactive red 6 (RR6) (ICI) was available, therefore, oil bodies was sensitised with RR6 in

order to be able to study specific deposition of oil bodies to surfaces.

0.1g oil bodies were resuspended in 4.8ml 0.1M  $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$ ,  
5 0.05M NaCl pH8.5, and 0.2ml 2% RR6 in water. The suspension was rotated overnight at room temperature. The sample was centrifuged at 13000rpm for 2 minutes, and the upper layer removed and Nile red added as described above.

10 1.4 Generation of anti-RR6 VHH-anti-Keratin VHH-CBD

Scavenging of oil bodies from solution and capture on cotton was performed using a molecule which had 2 VHH specificities fused to CBD ( $\alpha\text{RR6 VHH}-\alpha\text{keratin VHH-CBD}$ ).

15 1.4.1. Preparation of a Keratin Specific VHH from Llama

1.4.1.1 Antigen Preparation

Human plantar callus corneocytes were obtained by filing.  
Soluble callus extract was prepared by suspending 100mg  
callus corneocytes in 50ml 20mM Tris pH7.4 / 8M urea / 1% SDS,  
20 boiling for 15 minutes and then sonicating with an ultrasonic probe 22 $\mu$  for 2 minutes. The sample was centrifuged at 1,000g for 20 minutes at 15°C. The supernatant was recovered and dialysed against PBS overnight.

25 1.4.1.2 Immunisation Schedule

A llama, kept at the Dutch Institute for Animal Science and Health (ID-DLO, Lelystad), was immunised with callus  
corneocytes and subsequently boosted 2 times approximately 1 month apart. The serum used for library construction was  
30 removed 1 week after the second boost.

1.4.1.3 Polyclonal Sera Analysis

Sera were analysed by ELISA against callus soluble extract as follows:

1. Sterilin microtitre plate (Sero-Wel) was sensitised with  
35 100 $\mu$ l/well 25 $\mu$ g/ml callus extract in PBS. Plates were

incubated overnight at 4°C and then washed in PBS.

2. The plate was blocked by preincubating with 200µl/well 1% marvel in PBS containing 0.15% Tween (PBST) for 1 hour at 37°C.

5 3. Blocking buffer was removed and 100µl/well llama immunised sera or prebleed, beginning with a 10<sup>-1</sup> dilution in PBS, added. Incubations were for 1 hour at 37°C.

4. Unbound antibody fragment was removed by washing 4x using a plate washer in PBST.

10 5. 100µl/well of rabbit anti-llama VHH was added at an appropriate dilution in PBST. Incubation was for 1 hour at 37°C.

6. Plate was washed as described in step 3.

15 7. 100µl/well alkaline phosphatase conjugated goat anti-rabbit (Jackson) was added at an appropriate dilution in PBSTa and incubated for 1 hour at 37°C.

8. Plate was washed as described previously.

9. Alkaline phosphatase activity was detected by adding 100µl/well substrate solution: 1mg/ml pNPP in 1M

20 diethanolamine, 1mM MgCl<sub>2</sub>.

10. Absorbance was read at 405nm when the colour had developed.

#### 1.4.1.4 mRNA Isolation and cDNA synthesis

25 2.5x10<sup>8</sup> peripheral blood lymphocytes (PBLs) were isolated using a ficoll gradient. RNA was isolated based on the method of Chomczynski and Sacchi, (1997) Anal. Biochem., vol 162, pp 156-159. mRNA was subsequently prepared using Oligotex mRNA Qiagen Purification kit.

30

cdna was synthesised using First Strand Synthesis for RT-PCR kit from Amersham (RPN 1266) and the oligo dT primer.

Approximately 2 µg mRNA was used (1µg /Eppendorf) as estimated from the total RNA concentration and assuming that

35 mRNA constitutes 1% of the total RNA.

1.4.1.5 Isolation of short and long-hinge VHHs by PCR

A master mix for the amplification of short and long-hinge PCR was prepared as follows:-

5

46µl dNTP mix (5mM)

11.5µl LAM 07 or LAM 08 (100pmol/µl)

LAM 07: 5'

10 AACAGTTAAGCTTCCGCTTGCGGCCGCGAGCTGGGGTCTTCGCTGTGGTGCG

LAM 08: 5'

AACAGTTAAGCTTCCGCTTGCGGCCGCTGGTTGTGGTTTGGTGTCTTGGGTT

15 11.5µl VH2B (100pmol/µl)

VH2B: 5' AGGTSMARCTGCAGSAGTCWGG

S= C/G, M= A/C, W= A/T, R= A/G

20

115µl MgCl<sub>2</sub> (25mM)

161µl dep water

20 tubes for both short and long-hinge amplification were  
25 prepared containing 15µl/Eppendorf of the above master mix  
and 1 ampliwx (Perkin Elmer). Tubes were incubated for 5  
minutes at 75°C to melt the wax and then placed on ice.

35µl of the following appropriate mix was added to each  
30 Eppendorf:-

200µl 5x stoffel buffer (Perkin Elmer)

20µl Amplitaq DNA polymerase stoffel fragment (Perkin Elmer)

1140µl dep water

40µl cDNA



Negative controls had the cDNA omitted and replaced with dep water. The reaction conditions were: 1 cycle at 94°C 5 minutes; 35 cycles at (94°C 1 minute; 55°C 1.5 minutes; 77°C 2 minutes) and 1 cycle at 72°C 5 minutes. Identical reactions were pooled and 5µl was analysed on a 2% agarose gel.

#### 1.4.1.6 Restriction Enzyme Digestion of VHHs and pUR4536

Pooled llama short and long-hinge PCR products were purified from a 2% agarose gel using Qiaex II purification kit (Qiagen) and resuspended in a final volume of 80µl. 40µl of this sample was digested using Hind III and PstI (Gibco BRL) according to manufacturer's instructions. Digested PCR products were again purified as detailed above. pUR4536 (Figure 10) was similarly digested and purified.

#### 1.4.1.7 Generation of short and long-hinge VHH Libraries

Appropriate ratios of PCR product were combined with digested vector using DNA ligase (Gibco BRL) according to manufacturer's instructions. Ligation reactions were purified and used to transform electrocompetent *E. coli* JM109.

#### 1.4.1.8 Phage Rescue Maxiscale

15ml 2TY/Amp/Glucose (16g Tryptone, 10g yeast extract, 5g NaCl per litre, containing 2% glucose and 100µg/ml ampicillin) was inoculated with 100µl of glycerol stock of either short or long-hinge VHH library and phage rescues were performed. The cells were grown until log phase was reached and infected with M13K07 helper phage (Gibco BRL). Infected cells were pelleted and resuspended in 2TY/Amp/Kan to allow release of phage into the supernatant. After overnight incubation at 37°C, phage were pelleted and concentrated by PEG precipitation. The final phage pellet was resuspended in 3ml PBS in 2% BSA / 1% marvel and incubated for approximately

30 minutes at room temperature.

#### 1.4.1.9 Selection of Antigen Binding Phages: Panning

- Nunc-immunotubes were sensitised with either 1ml of 50µg/ml  
5 soluble callus extract in PBS, or PBS only (as a negative  
control) overnight at 4°C. The tubes were washed with PBS and  
preblocked with 2ml 2% BSA / 1% marvel in PBST at room  
temperature for about 3 hours.
- 10 Blocking solution was removed and 1ml of blocked phage  
solution was added to the immunotubes. Samples were incubated  
for 4 hours at room temperature.

- The tubes were washed 20x with PBST and 20x with PBS. Bound  
15 phage were removed with 0.5ml 0.2M glycine / 0.1M HCl pH2.2  
containing 10mg/ml BSA, and incubating at room temperature  
for 15 minutes. The solution was removed into a fresh tube  
and neutralised with 30µl 2M Tris. 200µl 1M Tris pH7.5 was  
added to the tubes.

- 20 The eluted phage were added to 9ml log-phase *E. coli* XL-1  
Blue. 4ml log-phase *E. coli* was also added to the  
immunotubes. Cultures were incubated for 30 minutes at 37°C  
without shaking to allow for phage infection of the *E. coli*.

- 25 The cultures were pooled as appropriate, pelleted,  
resuspended in 2TY and plated out on SOBAG plates (20g bact-  
tryptone, 5g bacto-yeast extract, 0.5g NaCl per litre, 10mM  
MgCl<sub>2</sub>, 1% glucose, 100 µg/ml ampicillin) for harvesting and  
30 the panning process was repeated a further 2 times.

#### 1.4.1.10 Generation of Soluble VHH Fragments

- Clones from the panned libraries were harvested and DNA was  
isolated from the cell pellets using Qiagen midi-prep kit.
- 35 DNA from each panned library was used to transform CaCl<sub>2</sub>

competent *E. coli* D29A1, which were plated out on SOBAG plates and grown overnight at 37°C. Individual colonies of freshly transformed *E. coli* D29A1 were picked and VHH expression induced on a microtitre plate scale using IPTG.

5

#### 1.4.1.11 Detection of Expression of Anti-Skin VHH-myc Constructs

Sterilin microtitre plate (Sero-Wel) was sensitised with either callus soluble extract or PBS only. Plates were  
10 blocked with 200µl/well 1% BSA/PBST for 1 hour at 37°C. 90µl crude *E. coli* supernatant was premixed with 45µl 2% BSA/PBS and added to the appropriate wells of the blocked plates. Incubation was for 2 hours at 37°C. Unbound fragment was removed by washing 4x with PBST. 100µl/well of an appropriate  
15 dilution of mouse anti-myc antibody (in house) in 1% BSA/PBST was added and incubated for 1 hour at 37°C. Plates were washed as previously and 100µl/well of an appropriate dilution of alkaline phosphatase conjugated goat anti-mouse (Jackson) in 1% BSA/PBST added and incubated as before.  
20 Plates were again washed and alkaline phosphatase activity was detected by adding 100µl/well substrate solution: 1mg/ml pNPP in 1M diethanolamine/1 mM MgCl<sub>2</sub>. When the colour had developed an absorbance reading at 405nm was taken. The clone VHH8 was identified as specifically binding to epidermal  
25 keratin.

#### 1.4.2 Preparation of anti-RR6 Specific VHH from Llama

Anti-RR6 VHH was isolated similarly to that of anti-keratin VHH as described by Linden, R (Unique characteristics of  
30 llama heavy chain antibodies, PhD Thesis, Utrecht University, Netherlands, 1999).

#### 1.4.3 Construction of anti-RR6-anti-keratin-CBD

Anti-RR6VHH was genetically fused to 6 histidines (for  
35 purification purposes) and CBD derived from *Trichoderma*

reesei (Linder M. et al, Protein Science, 1995, vol 4, pp. 1056-1064), and cloned into pPic9 (Figure 11). VHH8 (anti-keratin) was subsequently isolated from pur4536 by restriction enzyme digestion. Using BstEII, VHH8 was ligated  
5 between the anti-RR6 VHH and CBD sequence in pPic9. The clone was expressed in *Pichia pastoris*. The DNA sequence is shown in Figure 12.

### 1.5 Production and Analysis of Triple Head Biorecognition

#### 10 Molecule.

##### 1.5.1 Transformation and selection of transformed *P. pastoris* cells

Approximately 2-5µg DNA in 2µl water (TthI, SacI digested) pPic9 construct was used to transform electrocompetent *P.*  
15 *pastoris* GS115 (Invitrogen) according to manufacturer's instructions.

##### 1.5.2 Production and Evaluation of anti-RR6-VHH8-CBD

Transformed and selected *P. pastoris* clones were induced to  
20 express antibody using the protocol outlined below:

- 1) Using a single colony from the MD plate, inoculate 10ml of BMGY (1% Yeast Extract, 2% Peptone, 100mM potassium phosphate pH6.0, 1.34% YNB, 4x10<sup>-5</sup> % Biotin, 1% Glycerol) in a 50ml  
25 Falcon tube.
- 2) Grow at 30°C in a shaking incubator (250 rpm) until the culture reaches an OD<sub>600</sub>~2-8.
- 3) Spin the cultures at 2000g for 5 minutes and re-suspend the cells in 2ml of BMMY medium (1% Yeast Extract, 2%  
30 Peptone, 100mM potassium phosphate pH6.0, 1.34% YNB, 4 X10<sup>-5</sup> % Biotin, 0.5% Glycerol).
- 4) Return the cultures to the incubator.
- 5) Add 20µl of MeOH to the cultures after 24 hours to maintain induction.
- 35 6) After 48 hours harvest the supernatant by removing the

cells by centrifugation.

The crude supernatants were tested for the presence of antibody construct via analysis on 12% acrylamide gels using the Bio-Rad mini-Protean II system. VHH8 activity was detected as described section 1.4.1.11. Anti-RR6 activity was detected as follows:

- 1) 96 well ELISA plates (Greiner HB plates) were sensitised overnight at 37°C with 100 µl/well of BSA-RR6 conjugate (azo-dye RR6 (ICI) which was coupled to BSA via its reactive triazine group) in PBS, or PBS only.
- 2) Following one wash with PBST the wells were incubated for 1 hour at 37°C with 100 µl blocking buffer (1% BSA in PBST) per well.
- 3) Test supernatants (50µl) were mixed with equal volumes of blocking buffer and added to the sensitised ELISA wells. Incubated at 37°C for 1 hour.
- 4) Following 4 washes with PBST, 100µl rabbit anti-llama polyclonal sera (in house) was added at an appropriate dilution in blocking buffer. Incubated at 37°C for 1 hour.
- 5) Following four washes with PBST, goat anti-rabbit conjugated to alkaline phosphatase (Zymed) was added at an appropriate dilution in blocking buffer. Incubated at 37°C for 1 hour.
- 6) After washing 4 times with PBST, 100µl/well pNPP substrate (1mg/ml pNPP in 1M diethanolamine/1mM MgCl<sub>2</sub>) was added to each well. When colour had developed, plates were read at 405nm.

CBD binding activity was detected as follows:

- 1) 20µl 1% ethylcellulose and 80µl 0.1% marvel in PBST (blocking buffer), or blocking buffer only, were added to

wells of an MAHV 0.45 $\mu$  filter plate (Millipore). Incubated for 1 hour at room temperature with shaking.

2) Buffer was removed using a vacuum manifold.

3) Test supernatants (50 $\mu$ l) were mixed with equal volumes of blocking buffer and added to the ELISA wells. Incubated at room temperature for 1 hour, with shaking.

4) Following 10 washes with PBST, 100 $\mu$ l rabbit anti-llama polyclonal sera (in house) was added at an appropriate dilution in blocking buffer. Incubated at room temperature for 1 hour, with shaking.

5) Following 10 washes with PBST goat anti-rabbit conjugated to alkaline phosphatase (Zymed) was added at an appropriate dilution in blocking buffer. Incubated at room temperature for 1 hour, with shaking.

6) After washing 10 times with PBST, 100 $\mu$ l/well pNPP substrate (1mg/ml pNPP in 1M diethanolamine/1mM MgCl<sub>2</sub>) was added to each well. When colour had developed, substrate was removed to a new solid ELISA plate and optical density was measured at 405nm.

20

### 1.5.3 Large Scale Expression of Construct

The clone giving the best expression levels and binding activities was selected and produced on 3l fermentation scale in a fermenter. Purification was via the histidine tail using IMAC (Immobilised metal affinity chromatography).

25

### 1.6 Targeting of Oil Bodies to Cotton

Multiples of 4 lots of 2cm lengths of cotton fibres were placed in 3ml volume glass vials. The cotton was prewashed for 30 minutes in 1ml PBST with shaking. The buffer was decanted and replaced with 1ml of 25 $\mu$ g/ml anti-RR6-VHH8-CBD in PBS containing the detergent 0.15% Tween (PBST) or PBST only. Incubation was for 1 hour at room temperature with shaking. The samples were washed 3 x 5 minutes with 1ml PBST,

30

shaking at room temperature. Samples were then incubated for 1hour, room temperature, with shaking, with either of the following:-

100µl oil bodies containing nile red and 900µl PBST

- 5 100µl oil bodies containing nile red, sensitised with RR6 and 900µl PBST

1ml PBST only.

- 10 Samples were washed 3 x 10 minutes with 1ml PBST, followed by 3ml PBST for 10 minutes, with shaking at room temperature.

#### 1.6.1 Image Analysis

- 15 A single strand of treated cotton was laid onto a slide and a coverslip gently placed on top. The slides were viewed using a Bio-Rad MRC600 Confocal Scanning Laser Microscope (Bio-Rad Laboratories Ltd), attached to an Ortholux II microscope (Leica Microsystems UK Ltd), with 488nm laser excitation. A x4/0.12 LEITZ Plan objective (2) was used with a zoom factor of 2.0 to image the slides. Four areas were taken along each cotton strand at approximately equal distances. Each image area taken was 1795x1197µm. The black and gain levels for each set of images were set up using the negative control and then kept constant for the remainder of the samples.

- 25 The Bio-Rad CoMos software was used to capture, store and analyse the images. An image was opened and the Enhance and then Histogram options selected. A box was drawn and the aspect ratio changed to a square. This box was then resized to 150x150 pixels (12,2937.88µm<sup>2</sup>), which was used for all the measurements. The box was positioned five times randomly along the length of the fibre and the average pixel intensity within this box taken at each point. A visual record of each measurement area was also taken and printed. The values were exported into Microsoft Excel and the average of the average values calculated for each fibre.
- 35

Treatments involving oil bodies sensitised with RR6 cannot be directly compared to those containing Nile red only, since the application of equal concentrations of the two different preparations was not strictly controlled. However, the results clearly exemplify that deposition of oil bodies is significantly enhanced if the fabric is preprepared with a biorecognition molecule able to bind both cotton and scavenge particle from an aqueous environment, in the presence of detergent. Deposition of oil bodies not sensitised with RR6, and therefore, not able to bind  $\alpha$ RR6 VHH, was significantly less. Similarly, if no antibody was present, there was greatly reduced deposition of oil bodies. The negative controls of untreated cotton or cotton incubated with antibody only showed only very low levels of autofluorescence.



CLAIMS

1. A method of delivering a benefit agent to fabric for exerting a pre-determined activity, which comprises pre-  
5 treating said fabric with a multi-specific binding molecule, said binding molecule having a high binding affinity to said fabric through one specificity and is capable of scavenging and binding to said benefit agent through another  
10 specificity, followed by contacting said pre-treated fabric with said benefit agent to exert said pre-determined activity to said fabric.

2. The method of claim 1, wherein said binding molecule is an antibody, an antibody fragment, or a derivative  
15 thereof.

3. The method of claim 1, wherein said binding molecule is a fusion protein comprising a cellulose binding domain and a domain having a high binding affinity to another ligand.  
20

4. The method of any one of the preceding claims, wherein said area of a fabric comprises one or more stains, said pre-determined activity is bleaching activity, and said benefit agent is capable of generating a bleaching agent.  
25

5. The method of any one of the preceding claims, wherein said benefit agent is an enzyme or enzyme part capable of catalyzing the formation of a bleaching agent.

30 6. The method of claim 5, wherein said enzyme or enzyme part is an oxidase or haloperoxidase or functional part thereof.

7. The method of claim 6, wherein said oxidase is  
35 selected from the group consisting of glucose oxidase, galactose oxidase and alcohol oxidase.

8. The method of claim 6, wherein said haloperoxidase is a chloroperoxidase.

5 9. The method of claim 8, wherein said chloroperoxidase is a vanadium chloroperoxidase.

10. The method of claim 9, wherein said vanadium chloroperoxidase is a *Curvularia inaequalis* chloroperoxidase.  
10

11. The method of claim 1, wherein the said bleaching agent is hydrogen peroxide or a hypohalite, in particular a hypochlorite.

15 12. The method of any one of the preceding claims, wherein said benefit agent is a laccase or a peroxidase and said bleaching agent is derived from an enhancer molecule that has reacted with the enzyme.

20 13. The method of any one of the preceding claims, wherein said enzyme part is bound to said binding molecule having a high binding affinity for porphyrin derived structures, tannins, polyphenols, carotenoids, anthocyanins, and Maillard reaction products.

25 14. The method of any one of the preceding claims, wherein said enzyme part is bound to said binding molecule having a high binding affinity for porphyrin derived structures, tannins, polyphenols, carotenoids, anthocyanins,  
30 and Maillard reaction products when they are adsorbed onto the surface of a fabric.

15. The method of any one of the preceding claims, wherein the fabric is cotton, polyester, polyester/cotton, or  
35 wool.

16. The method of claim 2, wherein said antibody or said antibody fragment or said derivative thereof is all of part of a heavy chain immunoglobulin that was raised in *Camelidae* and has a specificity for stain molecules.

5

17. The method of claim 2, wherein said antibody or said antibody fragment or said derivative thereof bind to chemical constituents which are present in tea, blackberry and red wine including non-pigmented components of stains, for example pectins.

10

18. The method of claim 3, wherein said ligand binds to chemical constituents which are present in tea, blackberry and red wine including non-pigmented components of stains, for example pectins.

15

19. The method of any one of the preceding claims, wherein the binding molecule having a high binding affinity has a chemical equilibrium constant  $K_d$  for the substance of less than  $10^{-4}$  M, preferably less than  $10^{-6}$  M.

20

20. The method of claim 19, wherein the chemical equilibrium constant  $K_d$  is less than  $10^{-7}$  M.

21. The method of any one of the preceding claims, wherein said benefit agent is selected from the group consisting of fragrance agents, perfumes, colour enhancers, fabric softening agents, polymeric lubricants, photoprotective agents, latexes, resins, dye fixative agents, encapsulated materials, antioxidants, insecticides, anti-microbial agents, soil repelling agents, soil release agents, and cellulose fiber repair agents.

25

30

22. The method of any one of the preceding claims, wherein said benefit agent is comprised in an aqueous solution.

35

23. Detergent composition comprising oil bodies.

24. Detergent composition according to claim 23, wherein the oil bodies are obtained from rape seeds.

1/10

Fig.1.

pelB leader M K Y L L P T  
 AAGCTTGCATGCAAATTCATTTCAAGGAGACAGTCATAATGAAATACCTATTGCCTACG  
 A A A G L L L L A A Q P A M A Q V Q L Q  
 GCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCGATGGCCAGGTGCAGCTGCAG  
 E S G G D L V K P G G S L T L S C A T S  
 GAGTCAGGGGAGACTTAGTGAAGCCTGGAGGGTCCCTGACACTCTCCTGTGCAACCTCT  
 G F T F S S Y A F S W V R Q T S D K S L  
 GGATTCACCTTTCAGTAGTTATGCCTTTTCTGGGTCCGCCAGACCTCAGACAAGAGTCTG  
 VH4715 E W V A T I S S T D T Y T Y Y S D N V K  
 GAGTGGGTCGCAACCATCAGTAGTACTGATACTTATACCTATTATTCAGACAATGTGAAG  
 G R F T I S R D N G K N T L Y L Q M S S  
 GGGCGCTTCACCATCTCCAGAGACAATGGCAAGAACACCTGTACCTGCAATGAGCAGT  
 L K S E D T A V Y Y C A R H G Y Y G K G  
 CTGAAGTCTGAGGACACAGCCGTGTATTACTGTGCAAGACATGGGTACTATGGTAAAGGC  
 Y F D Y W G Q G T T V T V S S  
 TATTTTGACTACTGGGGCCAAGGACCAAGGTACCGTCTCCTCATAATAAGAGCTATGG  
 pelB leader M K Y L L P T  
 GAGCTTGCATGCAAATTCATTTCAAGGAGACAGTCATAATGAAATACCTATTGCCTACG  
 A A A G L L L L A A Q P A M A D I E L T  
 GCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCGATGGCCGACATCGAGCTCACT  
 Q S P F S L T V T A G E K V T M N C K S  
 CAGTCTCCATTCTCCCTGACTGTGACAGCAGGAGAGAAGGTCATATGAATTGCAAGTCC  
 G Q S L L N S V N Q R N Y L T W Y Q Q K  
 GGTCAGAGTCTGTTAAACAGTGTAAATCAGAGGAACACTTACCTGGTACCAGCAGAAG  
 VL4715 P G Q P P K L L I Y W A S T R E S G V P  
 CCAGGGCAGCTCCTAAACTGTTGATCTACTGGGCATCCACTAGGGAATCTGGAGTCCCT  
 D R F T A S G S G T D F T L T I S S V Q  
 GATCGCTTCACAGCCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAG  
 A E D L A V Y Y C Q N D Y T Y P F T F G  
 GCTGAAGACCTGGCAGTTTATTACTGTGCAAGATGATTATACTTATCCGTTACGTTCCGA  
 Myc-tag G G T K L E I K R E Q K L I S E E D L N  
 GGGGGGACCAAGCTCGAGATCAAACGGGAACAAAACACTCATCTCAGAAGAGGATCTGAAT  
 TAATAAGATCAAACGGTAATAAGGATCCAGCTCGAATTC

Nucleotide and amino acid sequence of the HindIII/  
 EcoRI insert of plasmid Fv4715-myc encoding pelB  
 leader-VH4715 and pelB leader-VL4715.

2/10

Fig.2.

pelB  
leader

M K Y L L P T

AAGCTTGCATGCAAATTCATTTC AAGGAGACAGTCATAATGAAATACCTATTGCCTACG

A A A G L L L L A A Q P A M A Q V Q L Q

GCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCGATGGCCAGGTGCAGCTGCAG

E S G G D L V K P G G S L T L S C A T S

GAGTCAGGGGAGACTTAGTGAAGCCTGGAGGGTCCCTGACACTCTCCTGTGCAACCTCT

G F T F S S Y A F S W V R Q T S D K S L

GGATTCACTTTTCAGTAGTTATGCCTTTTCTTGGGTCCGCCAGACCTCAGACAAGAGTCTG

VH4715

E W V A T I S S T D T Y T Y Y S D N V K

GAGTGGGTCCGAACCATCAGTAGTACTGATACTTATACCTATTATTTCAGACAATGTGAAG

G R F T I S R D N G K N T L Y L Q M S S

GGGCGCTTCACCATCTCCAGAGACAATGGCAAGAACACCCTGTACCTGCAAAATGAGCAGT

L K S E D T A V Y Y C A R H G Y Y G K G

CTGAAGTCTGAGGACACAGCCGTGTATTACTGTGCAAGACATGGGTACTATGGTAAAGGC

Linker

Y F D Y W G Q G T T V T V S S G G G G S

TATTTTGACTACTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTCA

G G G G S G G G G S D I E L T Q S P F S

GGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATCGAGCTCACTCAGTCTCCATTCTCC

L T V T A G E K V T M N C K S G Q S L L

CTGACTGTGACAGCAGGAGAGAAGGTCACTATGAATTGCAAGTCCGGTCAGAGTCTGTTA

VL4715

N S V N Q R N Y L T W Y Q Q K P G Q P P

AACAGTGTAATCAGAGGAACACTTGACCTGGTACCAGCAGAAGCCAGGGCAGCCTCTCT

K L L I Y W A S T R E S G V P D R F T A

AAACTGTTGATCTACTGGGCATCCACTAGGGAATCTGGAGTCCCTGATCGCTTCACAGCC

S G S G T D F T L T I S S V Q A E D L A

AGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCA

V Y Y C Q N D Y T Y P F T F G G G T K L

GTTTATTACTGTCAGAATGATTATACTTATCCGTTACAGTTCGGAGGGGGACCAAGCTC

Myc-tag

E I K R E Q K L I S E E D L N


GAGATCAAACGGGAACAAAACACTCATCTCAGAAGAGGATCTGAATTAATAAGATCAAACG

GTAATAAGGATCCAGCTCGAATTC

Nucleotide and amino acid sequence of the HindIII/  
EcoRI insert of plasmid scFv4715-myc encoding  
pelB leader-VH4715-linker-VL4715.

3/10

Fig.3.



Nucleotide and amino acid sequence of the HindIII/  
 EcoRI insert of plasmid Fv3299-hydro2 encoding  
 pelB leader-VH3299 and pelB leader-VL3299 with  
 hydrophil2 tail.

4/10

Fig.4.

pelB leader  
 AAGCTTGCAAATCTATTTC AAGGAGACAGTCATAATGAAATACCTATTGCCTACGGCAG  
 A A G L L L L A A Q P A M A Q V Q L Q Q  
 CCGCTGGATTGTTATTACTCGCTGCCCAACCAGCGATGGCCAGGTGCAGCTGCAGCAGT  
 S G P E L V K P G A S V K M S C K A S G  
 CAGGACCTGAGCTGGTAAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGAT  
 Y T F T S Y V M H W V K Q K P G Q G L E  
 ACACATTCAGTCTATGTTATGCACTGGGTGAAACAGAAGCCTGGGCAGGGCCTTGAGT  
 W I G Y I Y P Y N D G T K Y N E K F K G  
 GGATTGGATATATTTATCCTTACAATGATGGTACTAAGTACAATGAGAAGTTCAAAGGCA  
 K A T L T S D K S S S T A Y M E L S S L  
 AGGCCACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGCCTGA  
 T S E D S A V Y Y C S R R F D Y W G Q G  
 CCTCTGAGGACTCTGCGGTCTATTACTGTTCAAGACGCTTTGACTACTGGGGCCAAGGA  
 T T V T V S S  
 CCACGGTCACCGTCTCCTCATAATAAGAGCTATGGGAGCTTGCATGCAAATCTATTTC  
 M K Y L L P T A A A G L L L L  
 AGGAGACAGTCATAATGAAATACCTATTGCCTACGGCAGCGCTGGATTGTTATTACTCG  
 A A Q P A M A D I E L T Q S P S S M Y A  
 CTGCCCAACCAGCGATGGCCGACATCGAGCTCACCCAGTCTCCATCTTCCATGTATGCAT  
 S L G E R I T I T C K A S Q D I N T Y L  
 CTCTAGGAGAGAGAATCACTATCACTTGCAAGGCGAGTCAGGACATTAATACCTATTAA  
 T W F Q Q K P G K S P K T L I Y R A N R  
 CCTGGTTCCAGCAGAAACCAGGGAAATCTCCCAAGACCCTGATCTATCGTGCAAACAGAT  
 L L D G V P S R F S G S G S G Q D Y S L  
 TGCTAGATGGGGTCCCATCAAGGTTCACTGGCAGTGGATCTGGGCAAGATTATTCTCTCA  
 T I S S L D Y E D M G I Y Y C L Q Y D E  
 CCATCAGCAGCCTGGACTATGAAGATATGGGAATTTATTATTGTCTACAATATGATGAGT  
 L Y T F G G G T K L E I K R  
 TGTACACGTTCCGAGGGGGGACCAAGCTCGAGATCAACGGTAATAATGATCAAACGGT  
 ATAAGGATCCAGCTCGAATTC

VH3418  
 pelB leader  
 M K Y L L P T A A A G L L L L  
 AGGAGACAGTCATAATGAAATACCTATTGCCTACGGCAGCGCTGGATTGTTATTACTCG  
 A A Q P A M A D I E L T Q S P S S M Y A  
 CTGCCCAACCAGCGATGGCCGACATCGAGCTCACCCAGTCTCCATCTTCCATGTATGCAT  
 S L G E R I T I T C K A S Q D I N T Y L  
 CTCTAGGAGAGAGAATCACTATCACTTGCAAGGCGAGTCAGGACATTAATACCTATTAA  
 T W F Q Q K P G K S P K T L I Y R A N R  
 CCTGGTTCCAGCAGAAACCAGGGAAATCTCCCAAGACCCTGATCTATCGTGCAAACAGAT  
 L L D G V P S R F S G S G S G Q D Y S L  
 TGCTAGATGGGGTCCCATCAAGGTTCACTGGCAGTGGATCTGGGCAAGATTATTCTCTCA  
 T I S S L D Y E D M G I Y Y C L Q Y D E  
 CCATCAGCAGCCTGGACTATGAAGATATGGGAATTTATTATTGTCTACAATATGATGAGT  
 L Y T F G G G T K L E I K R  
 TGTACACGTTCCGAGGGGGGACCAAGCTCGAGATCAACGGTAATAATGATCAAACGGT  
 ATAAGGATCCAGCTCGAATTC


VL3418  
 pelB leader  
 M K Y L L P T A A A G L L L L  
 AGGAGACAGTCATAATGAAATACCTATTGCCTACGGCAGCGCTGGATTGTTATTACTCG  
 A A Q P A M A D I E L T Q S P S S M Y A  
 CTGCCCAACCAGCGATGGCCGACATCGAGCTCACCCAGTCTCCATCTTCCATGTATGCAT  
 S L G E R I T I T C K A S Q D I N T Y L  
 CTCTAGGAGAGAGAATCACTATCACTTGCAAGGCGAGTCAGGACATTAATACCTATTAA  
 T W F Q Q K P G K S P K T L I Y R A N R  
 CCTGGTTCCAGCAGAAACCAGGGAAATCTCCCAAGACCCTGATCTATCGTGCAAACAGAT  
 L L D G V P S R F S G S G S G Q D Y S L  
 TGCTAGATGGGGTCCCATCAAGGTTCACTGGCAGTGGATCTGGGCAAGATTATTCTCTCA  
 T I S S L D Y E D M G I Y Y C L Q Y D E  
 CCATCAGCAGCCTGGACTATGAAGATATGGGAATTTATTATTGTCTACAATATGATGAGT  
 L Y T F G G G T K L E I K R  
 TGTACACGTTCCGAGGGGGGACCAAGCTCGAGATCAACGGTAATAATGATCAAACGGT  
 ATAAGGATCCAGCTCGAATTC

Nucleotide and amino acid sequence of the HindIII/  
EcoRI insert of plasmid Fv3418 encoding pelB  
leader-VH3418 and pelB leader-VL3418.



5/10


Fig.5.



Nucleotide and amino acid sequence of the HindIII/  
 EcoRI insert of plasmid pUR4124 encoding pelB  
 leader-VLLys-linker-VHLys.

6/10


Fig.6.



7/10

Fig.7.

## Bi-head cloning strategy



**SUBSTITUTE SHEET (RULE 26)**

9/10

Fig.9.





Fig.10.



10/10

Fig.11.




Fig.12.

CAGGTGCAGCTGCAGGAGTCAGGGGGAGGATTGGTGCAGGCTGGGGGCTCTCTGAGACTC  
 TCCTGTGCAGCCTCGGGACGCGCCACCAAGTGGTCATGGTCACTATGGTATGGGCTGGTTC  
 CGCCAGGTTCCAGGGAAGGAGCGTGAGTTTGTTCGAGCTATTAGGTGGAGTGGTAAAGAG  
 ACATGGTATAAAGACTCCCGTGAAGGGCCGATTACCATCTCCAGAGATAACGCCAAGACT  
 ACGGTTTATCTGCAAATGAACAGCCTGAAACCTGAAGATACGGCCGTTTATTATTGTGCC  
 GCTCGACCGGTCCGCGTGGATGATATTTCCCTGCCGTTGGGTTTGACTACTGGGGCCAG  
 GGGACCCAGGTCACCGTCTCCTCACAGGTGCAGCTGCAGCAGTCTGGGGGAGGCTTGGTA  
 CAGCCTGGGGGGTCTCTAAGACTCTCTGTGAAGCCTCTGGGTTTCATCTTCAGTAGCAGA  
 GCGATGTCTGGTATCGCCAGGGTCCAGGGAAGCAGCGCGAGCCGGTTCGCATTTATTTCT  
 ACTGGTGGTGATACAACTATGCTAACTCCGTGAAGGGCCGATTACCATCTCCAGAGAC  
 AACGCCAAGAACACGGTAGATCTGCAAATGAACAATTTAAACCTGAGGACACGGCCGTC  
 TATTACTGTAAGACAATAGTCGAAAAGGACTACTGGGGCCAGGGGAACCAAGGTCACCGTC  
 TCCTCAGGATCTCATCACCATCACCATCACGGATCCACCTCCATTGAAGGTCGTACCCAG  
 TCTACTACGGTCAGTGTGGTGGTATTGGTACTCCGGTCCAACCGTCTGTGCCTCTGGT  
 ACCACCTGTCAGGTTCTGAACCCTTACTACTCCAGTGTCTGTAATAA

DNA Sequence of anti-RR6-VHH8-his-CBD

(12)

(21) 2 395 138

(22) 08.12.2000

(51) Int. Cl. 7: **D06M 16/00, C11D 17/04,  
D06L 3/11, D06M 15/15,  
C11D 3/384, C11D 3/386**

(85) 17.06.2002

(86) PCT/EP00/12530

(87) WO01/046514

(30) 99310427.2 EP 22.12.1999

(71) **UNILEVER PLC,  
Unilever House  
Blackfriars  
EC4P 4BQ, LONDON, XX (GB).**

**SMITH, RICHARD GEORGE (GB).  
PARRY, NEIL JAMES (GB).  
VAN DER LOGT, CORNELIS PAUL ERIK (NL).  
LITTLE, JULIE (GB).  
HOWELL, STEVEN (GB).  
HEMMINGTON, SANDRA (GB).**

(72)


(74) **BERESKIN & PARR**

(54) TRAITEMENT DE TISSUS ET APPAREIL UTILISE A CET EFFET

(54) METHOD OF TREATING FABRICS AND APPARATUS USED THEREIN

(57)

There is provided a method of delivering a benefit agent to a selected area of a fabric for exerting a predetermined activity, wherein the area is pre-treated with a multi-specific binding molecule which has a high binding affinity to said area through one specificity and is capable of binding to said benefit agent through another specificity, followed by contacting said pre-treated area with said benefit agent, to enhance said pre-determined activity to said area. Preferably, the binding molecule is an antibody or fragment thereof, or a fusion protein comprising a cellulose binding domain and a domain having a high binding affinity to another ligand which is directed to said benefit agent. The method is useful for stain removal, perfume delivery, and treating collars and cuffs for wear. Also provided is a device for use in this method, which is a dispenser capable of depositing a multi-specific binding molecule to a selected area of a fabric through a semi-solid wax or soap-stick, spray, aerosol, impregnated brush, gel, or foam, and the like.





Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2395138 A1 2001/06/28

(21) 2 395 138

(12) DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2000/12/08

(87) Date publication PCT/PCT Publication Date: 2001/06/28

(85) Entrée phase nationale/National Entry: 2002/06/17

(86) N° demande PCT/PCT Application No.: EP 2000/012530

(87) N° publication PCT/PCT Publication No.: 2001/046514

(30) Priorité/Priority: 1999/12/22 (99310427.2) EP

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> D06M 16/00, C11D 3/386, C11D 3/384, C11D 17/04, D06M 15/15, D06L 3/11


(71) Demandeur/Applicant:  
UNILEVER PLC, GB

(72) Inventeurs/Inventors:  
HEMMINGTON, SANDRA, GB;  
HOWELL, STEVEN, GB;  
LITTLE, JULIE, GB;  
VAN DER LOGT, CORNELIS PAUL ERIK, NL;  
PARRY, NEIL JAMES, GB;  
SMITH, RICHARD GEORGE, GB

(74) Agent: BERESKIN & PARR

(54) Titre : TRAITEMENT DE TISSUS ET APPAREIL UTILISE A CET EFFET

(54) Title: METHOD OF TREATING FABRICS AND APPARATUS USED THEREIN



(57) Abrégé/Abstract:

There is provided a method of delivering a benefit agent to a selected area of a fabric for exerting a predetermined activity, wherein the area is pre-treated with a multi-specific binding molecule which has a high binding affinity to said area through one specificity and is capable of binding to said benefit agent through another specificity, followed by contacting said pre-treated area with said benefit agent, to enhance said pre-determined activity to said area. Preferably, the binding molecule is an antibody or fragment thereof, or a fusion protein comprising a cellulose binding domain and a domain having a high binding affinity to another ligand which is directed to said benefit agent. The method is useful for stain removal, perfume delivery, and treating collars and cuffs for wear. Also provided is a device for use in this method, which is a dispenser capable of depositing a multi-specific binding molecule to a selected area of a fabric through a semi-solid wax or soap-stick, spray, aerosol, impregnated brush, gel, or foam, and the like.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPQ 191

OPIC



CIPQ